medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Preprint, Ver. 1 (June 24, 2020) - *the manuscript has not been peer-reviewed yet.*

Estimating the global spread of COVID-19

Hazhir Rahmandad[1*], Tse Yang Lim[1], John Sterman[1]

[1]Sloan School of Management, Massachusetts Institute of Technology, Cambridge, MA

Corresponding author:
*hazhir@mit.edu

Data, codes, and simulation models:
https://github.com/tseyanglim/CovidGlobal

Declaration of Interest:
The authors declare no competing interests.

Acknowledgements:
We thank Tom Fiddaman and Ventana Systems for providing us with experimental Vensim parallel simulation engine.

Funding:
No funding was used to conduct this study.

Number of pages:
Main text: 11
Supplementary document: 45

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Estimating the global spread of COVID-19

Hazhir Rahmandad, PhD[1*], Tse Yang Lim[1], John Sterman[1]

[1]Sloan School of Management, Massachusetts Institute of Technology, Cambridge, MA

ABSTRACT

Limited and inconsistent testing and differences in age distribution, health care resources, social distancing, and policies have caused large variations in the extent and dynamics of the COVID-19 pandemic across nations, complicating the estimation of prevalence, the infection fatality rate (IFR), and other factors important to care providers and policymakers. Using data for all 84 countries with reliable testing data (spanning 4.75 billion people) we develop a dynamic epidemiological model integrating data on cases, deaths, excess mortality and other factors to estimate how asymptomatic transmission, disease acuity, hospitalization, and behavioral and policy responses to risk condition prevalence and IFR across nations and over time. For these nations we estimate IFR averages 0.68% (0.64%-0.7%). Cases and deaths through June 18, 2020 are estimated to be 11.8 and 1.48 times official reports, respectively, at 88.5 (85-95.3) million and 600 (586-622) thousand. Prevalence and IFR vary substantially, e.g., Ecuador (18%; 0.61%), Chile (15.5%; 0.57%), Mexico (8.8%; 0.69%), Iran (7.9%; 0.44%), USA (5.3%; 0.99%), UK (5.2%; 1.59%), Iceland (1.65%, 0.56%), New Zealand (0.1%, 0.64%), but all nations remain well below the level needed for herd immunity. By alerting the public earlier and reducing contacts, extensive testing when the pandemic was declared could have averted 35.3 (32.7-42.7) million cases and 197 (171-232) thousand deaths. However, future outcomes are less dependent on testing and more contingent on the willingness of communities and governments to reduce transmission. Absent breakthroughs in treatment or vaccination and with mildly improved responses we project 249 (186-586) million cases and 1.75 (1.40-3.67) million deaths in the 84 countries by Spring 2021.

INTRODUCTON

Effective response to the COVID-19 pandemic requires an understanding of its global magnitude and risks. Yet more than 15 weeks after WHO declared a global pandemic, we do not know the true number of cases nor the infection fatality rate. The data we do have are highly variable; as of late June, 2020, countries have reported cumulative cases ranging between 0.18 and 2850 per 100,000 and deaths to cases (approximate case fatality rates: CFR) ranging between 0 and 24%. We do not fully know what explains such large variance. Establishing such basic measures has partly been slowed by a large asymptomatic fraction (*1*) and similarity of COVID-19 symptoms with other common illnesses (*2*). Moreover, official case and fatality data are generated through testing. Dramatic variation in testing rates across countries (*3*), differences in attribution of deaths to COVID-19, and significant false negative rates (*4-6*) complicate assessment of the true magnitude of the pandemic from official data. The inference problem also requires disentangling other

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

explanatory mechanisms: A) Differences in population density, lifestyle, and interaction patterns create variations in reproduction number. B) Risk perception, behavioral change and policy responses alter transmission rates endogenously. C) Testing is prioritized based on symptoms and risk factors, so detection rates depend on both testing rates and current prevalence. D) Limited hospital capacity is allocated based on symptoms, influencing fatality rates. E) Weather may have a role in transmission (*7*) while age, socio-economic status, and pre-existing conditions impact severity (*8, 9*), with the poor and minorities suffering disproportionately (*10*).

Prior research has addressed different parts of this puzzle, including estimating the infection fatality rate (IFR) in well-controlled settings (*11*) or using statistical extrapolation (*12*), assessing the asymptomatic fraction in smaller populations or through random testing (*13, 14*), and estimating prevalence using random antibody testing in highly affected cities and regions (*15*). Yet we lack a global view of the pandemic that is both consistent with these more focused findings and simultaneously explains the large variance in official cases and fatality across different countries.

In this paper we build and estimate a multi-country model of the COVID-19 pandemic at global scale. Our model captures transmission dynamics for the disease, as well as how, at the country level, transmission rates vary in response to risk perception and weather, testing rates condition infection and death data, and fatality rates depend on demographics and hospitalization. Estimating this model using data from every country with more than 1000 cases for which testing data is available, we infer some of the key characteristics of COVID-19 pandemic globally and inform how alternative control policies may have played out across the globe.

METHODS

Model

We use a multi-country modified SEIR model to simultaneously estimate the transmission of COVID-19 in 84 countries. The model tracks community transmission, excluding the global travel network and instead separately estimating the date of introduction of patient zero for each country. Within each country, the core of the model tracks the population through susceptible, pre-symptomatic, infected pre-testing, infected post-testing, and recovered states. Basic transmission dynamics reflect a classical SEIR process, with a baseline transmission rate, incubation period, and duration of infection. Building on this basic structure the model explicitly represents the dynamics of COVID testing, including demand for tests, sensitivity of PCR based testing, and allocation of test capacity between positive and negative cases, as well as the dynamics of hospital system capacity, both with concomitant effects on transmission and mortality. It also endogenously generates population-level behavioral and policy responses due to the perceived risks and government intervention.

A novel feature of our model is representing the severity of COVID-19 infection using a zero-inflated Poisson distribution. Zero severity indicates asymptomatic infection; increasing severity influences mortality and transmission, as well as chances of getting tested or hospitalized. The testing sector of the model uses country-level data for daily testing rates (See S3 for details). A (small) portion of testing is conducted post-mortem, on deceased individuals who were symptomatic but previously untested. Remaining testing is conducted on living individuals, consisting of a mix of symptomatic COVID-

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

infected people and those with other risk factors (e.g. hospital workers) or similar symptoms due to other illnesses. We assume, based on prior research (*16*), that infected individuals are potentially tested on average 5 days after the onset of symptoms. On any given day, individuals with more severe symptoms get priority for testing. Following (*17*), this prioritization exerts a selection effect that results in different average severity of COVID in the tested vs. untested infected populations. We also assume a 30% false negative rate for PCR-based COVID tests (*4, 5*). A positive test results in reduced contact rates for tested individuals, changing the transmission rates endogenously. Thus the model tracks various mechanisms generating the observable measures: a daily reported infection rate that combines the total positive results from each day's tests with daily post-mortem infection confirmations, and a daily reported death rate of confirmed cases. Unobserved parameters, such as IFR and asymptomatic fraction, can then be estimated by fitting the model against data for observables.

We estimate the effective hospital capacity for each country as a function of total hospital beds available, modified for population density. This modification approximates the effect of geographic heterogeneity in demand for hospital capacity – in larger and less densely populated countries, geographic heterogeneity in the progression of the epidemic means that some areas (e.g. New York city) may be overwhelmed with demand even when other parts of the country have unused hospital capacity. As with testing, hospital capacity is allocated between more severe COVID cases (both those tested and those not tested) and demand from non-COVID patients. Hospitalization can reduce the mortality rate for COVID patients, while other determinants of fatality rates are the severity of symptoms and the age distribution of the population (*8, 9*).

Each country also exhibits a response to the perceived risk of COVID. The response is endogenously driven by a weighted combination of reported and actual hazard of infection. Perceived risk drives reduction in contact rate and hence transmission rates through non-pharmaceutical interventions such as social distancing measures. Specific government policies are not explicitly represented, but treated as part of this endogenous risk response. Different countries could vary in their risk perception, response time, as well as the magnitude of their response based on the perceived risk.

Overall each country is represented by a system of ordinary differential equations tracking seven population stocks (Susceptible, Pre-symptomatic Infected, Infected Pre-testing, and four groups of Infected post-testing – positively tested or not × hospitalized or not) and a state variable for perceived risk. The model also includes multiple additional state variables for measurement and accounting of e.g. deaths and recoveries.

Estimation

Model parameters are specified based on prior literature and formal estimation. Main parameters adopted from the literature include incubation period (5 days (*8, 16*)), onset-to-detection delay (5 days (*16*)), sensitivity of PCR-based testing (70% (*4, 5*)), and post-detection illness duration (10 days (*8*)).

We estimate the remaining parameters using a maximum likelihood approach. Using testing rate time series and various country-level data points (e.g. population, hospital capacity, comorbidities, age distribution), the model endogenously simulates confirmed new daily cases and deaths over time and matches them against observed data by maximizing the likelihood of observing those data given the model parameters. We use a negative binomial likelihood function to accommodate excess dispersion in infection and death flows compared to more common Gaussian specifications. Where data on

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

excess mortality is available, we also include a likelihood-based penalty for model simulations deviating significantly from excess mortality not accounted for in official COVID-19 deaths.

The estimation uses a hierarchical Bayesian framework, where country-level parameters are drawn from global distributions for each parameter that enforce consistency across countries. For example, different countries would vary in how much hospital treatment reduces fatality but they should not be too far apart. We represent these variations with a Normal distribution with an underlying (unknown) mean and a variance that reflects the magnitude of heterogeneity expected across countries. For example, basic parameters regulating infection fatality rate should be highly similar across countries (i.e. low global variance), whereas parameters specifying the introduction of patient zero or policy choices could vary more widely. We set each parameter's cross-country variance to capture those differences. Using this random-effects method (*18*) we account for country-level heterogeneity while incorporating the commonality across countries for each model parameter and avoiding overfitting the model to data. Uncertainty in estimations and projections is then quantified using a Markov Chain Monte Carlo method designed for high dimensional parameter spaces (*19*). Estimation details are explained in appendix S2.

DATA

We analyzed any country with a) at least 1000 confirmed cases of COVID-19 by June 18; and b) enough test data to enable the interpolation of historical testing trajectory. 84 countries satisfied these criteria, including all disease hotspots to date with two notable exceptions, China and Brazil, for which reliable testing data could not be found. Time series data for daily infection and death counts by country are taken from the Johns Hopkins Center for Systems Science and Engineering's COVID-19 database (*20*). Test data are drawn from OurWorldInData portal (*3*) and augmented by US testing data (*21*) and compiling daily snapshots of COVID-19 testing globally collected in the Wikipedia page for "COVID-19 testing" (*22*) since March 11, 2020. To account for potential differences in reporting delays for infection, death, and testing data, missing daily data points in test counts, and weekly reporting cycles, we applied a pre-processing algorithm to the time series data (see S3 for details). National-level data on demographics, population density, hospital capacity, and healthcare indicators come from the World Bank and World Health Organization (*23, 24*). For excess mortality we use data compiled by the New York Times (*25*), BBC (*26*), and academic researchers (*27*) for a subset of countries.

Replicability

Supplements S1 and S5 provide full model equations. All models and data are publicly available on a GitHub repository, which also includes material for the replication of results.

RESULTS

The model is fitted against data for infections and deaths across 84 countries. We also report goodness-of-fit statistics for cumulative cases and deaths. Figure 1-A provides comparisons for a sample of larger countries; see S4 for the full sample. Global mean absolute errors (normalized by

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

mean) are 2.2% (9.4% for median across countries, Med) and 8.4% (Med: 10.2%) for cumulative infections and deaths, respectively. R-square values exceed 0.9 for 56% of 336 country-specific cumulative and incidence time series. Our projections are also consistent with excess mortality data, where available (see appendix S4). Main findings include estimated parameters of COVID-19 epidemics across countries, as well as trajectories of key measures. For estimated parameters we report a) the mean of most likely values across countries (Mean); b) the standard deviation of those values (Std), which quantifies variability of the underlying concept across countries; and c) the mean of country-level interquartile ranges (MIQR), which captures the inherent uncertainty in parameter estimates for each country.



Figure 1-Simulated trajectories of epidemic in countries with more than 60 million population and 40,000 confirmed cases. A) Comparison of model (solid) with data (dashed or dotted) for daily new confirmed cases (blue; left axis in thousands) and daily new confirmed deaths (red, right axis in thousands). B) Estimated actuals (with 95% CI in dotted lines) for cumulative cases (blue; left axis in millions) and cumulative deaths (red; right axis in thousands).

The model brings together infection, testing, risk perception, behavioral and policy responses, hospitalization, and fatality using data from across the globe. Here we focus on three main results.

First, the magnitude of epidemic is widely under-reported with much variation globally. We estimate the asymptomatic fraction to be 55% (Mean; Std: 0.6%; MIQR: 3.7%). Combined with a sensitivity of 70% (*4, 5*) for PCR tests, the fraction of infections that could potentially be identified without mass testing is limited to 32%. Most countries do not reach this upper bound, however, and testing is the binding constraint. Figure 2-A reports the ratio of estimated to reported infections and deaths, ranging between 2.4 and 157 for infections and 0.65 to 27 for deaths. In our sample of 84 countries (total population of 4.675 billion), we estimate total infections at 88.5 (85-95.3, 95% Credible Interval (CI)) million and 600 (CI: 586-622) thousands by June 18 2020, 11.8 and 1.48 times larger than reported numbers respectively. Under-counting has been larger earlier in the epidemic. For example, USA faced peak infection rate (of 395 thousands per day) when detection rate was less than 10% of daily new cases. The most affected countries (based on percent infected) to date include Ecuador (18%), Peru (16.6%), Chile (15.5%), Mexico (8.8%), Iran (7.9%), Qatar (7.3%), Spain (7.1%), USA (5.3%), UK (5.2%), and Netherlands (4.8%) (See Figure 1-B). Despite the order-of-magnitude under-reporting of cases, however, herd immunity due to infection remains far from reach (Figure 2-B). The closest a

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

country has come to herd immunity is Chile, which at its peak infection rate was 194 (CI: 150-213) days away from infection of 80% of its total population.

Second, we quantify both significant heterogeneity, and notable consistency, across countries in terms of basic parameters of the epidemic. The estimated initial reproduction number R_E ranges between 1.24 (Indonesia) and 10.28 (Iran), with the median of 4.5 (Iceland) (R_E estimates include significant uncertainty; See Figure S6 for details). Even absent endogenous reductions in contact due to realized risk, these initial rates may be higher than longer-term levels for most countries because of early exposures happening in denser social networks. Cross-country variations also reflect differences in population density, cultural practices, hygiene, as well as the timing of infection and thus early preparedness. We find support for the impact of weather on reproduction number, with the multiplier (R_W) developed by Xu and colleagues (*7*) explaining transmission rates closely ($R_W^{0.76}$). We estimate the global infection fatality rate (IFR) to have been 0.68% (CI: 0.64%-0.70%), with a wide range (Figure 2-C) between 0.14% (CI: 0.12-0.16; Qatar) and 2.08% (CI: 1.73-2.28; Italy). The variations in IFR are primarily due to demographics with elderly having much higher risks (*9*). Hospital availability and treatment effectiveness provide a second mechanism affecting fatality rates. We find that hospitalization can bring down risk of death to 39.5% (Std: 17.8%; MIQR: 7.9%) of baseline. The model explains much variability in IFR with minimum country-level variability in basic fatality parameters. Nevertheless, the quality of fit deteriorates in a handful of countries. For example, a ratio of simulated to reported deaths below one in a handful of countries signals that the model expected fewer deaths than observed. Notably, we find it hard to reconcile, using only the model's mechanisms, the low fatality rates in Qatar, Singapore, and Thailand relative to infection statistics, and high fatality rates in Belgium and France.

Third, testing regulates transmission dynamics though a few mechanisms. By providing early warning, testing sets in motion the behavioral and policy responses essential to reducing transmission rate and controlling the epidemic. The exponential nature of contagion amplifies small early differences, such that a few days' difference in response time can lead to large differences in peak infection and final epidemic size. Behavioral and policy responses to changes in infection risk are adopted rapidly, on average reducing effective contact (and thus transmission) rates in 13.5 (std: 7.1; MIQR: 3.8) days. Those responses are relaxed when risks attenuate, though down-regulating risk perception is slower (mean: 70.0; std: 31.2; MIQR: 49.2 days). Given limited data on rebounds in infections to date, how quickly perceived risk is downgraded is a major source of uncertainty in projecting the future of the pandemic. We also find that those with a positive test reduce their infectious contacts to a fraction of the original level (Mean: 11.8% of original contact rate; Std: 2.3%; MIQR: 11.0%). These reductions are especially important because asymptomatic individuals are estimated to be less infectious than symptomatic ones (Mean: 28%; Std: 0.68%; MIQR: 2.4%). Finally, by regulating infection rates through the previous two channels, testing also 'flattens the curve', allowing a larger fraction of those in need of medical care to be hospitalized. Together, these mechanisms create an early race between testing and the spread of infection (Figure 3). When infection is ahead, detection is compromised (moving up into the darker shades in figure), responses lag further, and exponential infection growth can overwhelm hospital capacity. High early test capacity and its rapid expansion (moving to the right in the figure), brings the epidemic to light, activates policy responses, and allow for control.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .



Figure 2-Country level estimates. A) Ratio of estimated to reported cases (blue circles; left log scale) and deaths (red squares; right log scale). B) Time to 80% cumulative infection based on current infection rates (blue circles) and peak infection rates to-date (red squares) in days (log scale). C) Estimated infection fatality rates in percentages. D) End of winter 2021 projections for cumulative cases (blue circle; left log scale) and deaths (red square, right log scale) as fraction of population. Assumes baseline estimated response functions and test rates moving to 20% of the range between current levels and 0.1% population per day.

Figure 4 (Panels A and B) shows one alternative testing scenario and counter-factual trajectories of pandemic to date. In this scenario, all countries shift their testing rates from baseline to 0.1% of population per day (a rate currently achieved by multiple countries, e.g. USA, Australia, in Figure 3). The shift happens on March 11, 2020 (the date COVID-19 was officially designated as a pandemic). Such enhanced testing would have reduced total cases from 88.5 millions to 53.2 (CI: 50.5-59.6) millions. Corresponding reduction in deaths would have been from 600k to 403k(CI: 377k-438k).

By making additional assumptions on future testing and responses, the model can inform future trajectories. We explore a few projections out to spring 2021 that exclude vaccine and treatment availability. Figure 4 (panels C and D) shows projections under three scenarios: I) using the current country-specific testing rates and response functions moving forward; II) if enhanced testing (of 0.1% per day) is adopted on July 1st 2020p; and III) if sensitivity of contact rate to perceived risk is set to 8 (approx. 70th percentile of estimated value across countries), leaving testing at current levels. Contrary to the impacts of early differences in testing (Figure 4-A), the reductions in future cases from additional testing (II) are rather modest (from 1.55 in I to 1.37 billions in II), because recognition of epidemic is no longer the bottleneck to response. Both these scenarios project a very large burden of new cases in the fall 2020, with hundreds of millions of cases concentrated in a few countries estimated

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

to have insufficient responses given perceived risks (primarily India, but also Bangladesh, Pakistan, and USA). In contrast, changes in response policies would make a major difference. Scenario III brings down future cases sharply, to as low as 153 (CI: 147-170) millions (cumulatively) by the end of winter.



Figure 3-Detection rates as a function of testing and infection rates (underlying colormap). Overlay plots: historical trajectories of 6 countries (selected for variance in testing and size of population and infection) showing (estimated) actual daily infections and daily tests performed (averaged over 15 day moving window for smoothness). Markers are one week apart, signaling the transition speed across different regions of input space.

Across scenarios, we find that the infection rate in each country usually peaks and then stabilizes at a lower and slowly declining linear rate, in some cases after damped oscillations (i.e. second waves). These (approximately) steady-state infection rates are at levels that motivate just enough policy and behavioral response to bring effective reproduction number R_E to 1. Faster rates lead to exponential growth, raise alarms and bring down contacts; slower ones lead to relaxation of policies bringing the reproduction number back up to 1. Those post-peak infection rates vary widely across countries and depend on risk perception parameters, time constants, and contact sensitivity to risk, as well as weather and susceptible population size.

Figure 2-D shows country-level details for another projection for cumulative infection and death rates (as percentage of population) at the end of winter 2021. In this scenario we shift both testing and contact sensitivity to perceived risks to arguably more realistic values between current ones and those in scenarios II and III in Figure 4-C. Specifically, on July 1st 2020 we shift test rates to a value 20% between the current rates and 0.1% per day (which increases testing in most countries and reduces it in a few). Similarly, sensitivity of contacts to perceived risk is shifted to 20% of the way between estimated country-level values and a high value of 8. Resulting infection and death rates at the end of this period reflect the post-peak burden of the disease discussed above and are estimated at 0.01% (CI: 0.005-0.045) and 7.9e-5% (CI: 4.4e-5-3.3e-4) of global population per day. The top ten countries by projected daily infection rates at the end of winter 2021 are India (287 thousand infections per day), USA (95.4), South Africa (20.6), Iran (17.0), Indonesia (13.2), UK (4.2), Nigeria (4.0), Turkey (4.0), France (3.3), and Germany (3.0). Appendix S4 provides projections for all countries. Note that projections are highly sensitive to assumed testing, behavioral, and policy responses in the scenario. As such they should be interpreted as indicators of potential risk and not precise predictions of future cases; more rigorous testing and reductions in contacts in response to risk perception will significantly reduce future cases while laxer response and normalization of risks can lead to overwhelming breakouts.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .



Figure 4-Counter-factual (A and B) and future (C and D) projections with 95% CI. A and B) Global estimated (solid lines) cumulative cases (A; blue) and deaths (B; red) compared with counterfactual (dashed line) where testing rates shift (with a month-long time constant) towards 0.1%/day starting March 11, 2020. C and D) Global projections for cumulative cases (C; blue) and deaths (D; red) until 3/20/2021 under current test rates (solid) line and alternative policy of shifting test rates towards 0.1%/day starting July 1st 2020 (dashed line).

Limitations

To enable empirical estimation and considering limits to data availability at a global scale, the model includes important simplifications and uncertainties that should temper the interpretation of the results. First, by analyzing an aggregate, country-level model, we abstract away much heterogeneity, from social networks to super-spreaders and local events. Moreover, we offer no explanation for the underlying heterogeneity in reproduction numbers across countries. Second, lacking hospitalization data across the world, the model's hospital sector includes additional uncertainty. Similarly, our estimated behavioral and policy response functions do not tease apart the impact of various determinants such as national and local policies, business and event closures, use of personal protective equipment, reductions in physical interactions, and a host of other contributors. Thus, results are not informative about the effectiveness of specific policies, and extrapolation of response function in future scenarios includes unknown uncertainties. For example, if normalization of risk reduced response magnitude in the second wave, our projections would miss that and prove optimistic. Finally, absent explicit travel network our results would under-estimate the risk of the re-introduction of the disease in locations that have contained the epidemic.

DISCUSSION

This paper provides a systemic view of the COVID-19 pandemic globally. By incorporating testing capacity and prioritization, hospitalization, and risk perception and responses into an epidemiological model, we are able to closely match widely varying country-specific trajectories of the epidemic. Our model explains the observed heterogeneities primarily through three pathways. First, estimates point to much variance in initial reproduction numbers across countries. This heterogeneity is not surprising given that reproduction number is very much a function of human behaviors and interaction

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

environments. Nevertheless, our study was not designed to tease out the sources of that heterogeneity, an important task that requires other types of data and analysis. Second, the course of the epidemic is also significantly impacted by risk perception and behavioral and policy responses that vary notably across different countries. Finally, we show that differences in testing rates play an important role in shaping those trajectories.

Despite those variations, we also find much that is consistent across the globe: a) We estimate that just over half of the infections are asymptomatic, consistent with detailed estimates from smaller samples (*1, 13, 14*). b) We estimate that asymptomatic individuals are about a third as infective as symptomatic patients. c) In our model, hospitalization brings down fatality substantially, highlighting the crucial importance of keeping cases below hospital capacity. d) We find an average global infection fatality rate close to 0.68%. This is consistent with growing evidence on IFR (*11, 28*). Our estimates for IFR change predictably with age, and require few other predictors and no country-specific factors to stay consistent with the data. e) An order of magnitude under-reporting of cases is the norm across most countries, with a few percent of population already infected across many nations; nevertheless, herd immunity remains distant. f) Finally, absent notable improvements in country level responses or breakthroughs in vaccination or treatment, the outlook for the epidemic remains grim, with most nations settling into a steady state of cases and deaths that, while below their peaks, are troublingly large.

REFERENCES

1. D. F. Gudbjartsson *et al.*, Spread of SARS-CoV-2 in the Icelandic population. *New England Journal of Medicine*, (2020).
2. W. Yang *et al.*, Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): A multi-center study in Wenzhou city, Zhejiang, China. *Journal of Infection*, (2020).
3. M. Roser, H. Ritchie, E. Ortiz-Ospina, J. Hasell, in *Our World in Data*. (2020).
4. W. Wang *et al.*, Detection of SARS-CoV-2 in different types of clinical specimens. *Jama* **323**, 1843-1844 (2020).
5. Y. Fang *et al.*, Sensitivity of chest CT for COVID-19: comparison to RT-PCR. *Radiology*, 200432 (2020).
6. Y. Li *et al.*, Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19. *J Med Virol* **92**, 903-908 (2020).
7. R. Xu *et al.*, Weather Conditions and COVID-19 Transmission: Estimates and Projections. *medRxiv*, (2020).
8. W. J. Guan *et al.*, Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* **382**, 1708-1720 (2020).
9. Z. Wu, J. M. McGoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. *Jama* **323**, 1239-1242 (2020).
10. A. V. Dorn, R. E. Cooney, M. L. Sabin, COVID-19 exacerbating inequalities in the US. *Lancet* **395**, 1243-1244 (2020).
11. T. W. Russell *et al.*, Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020. *Euro Surveill* **25**, (2020).
12. A. Basu, Estimating The Infection Fatality Rate Among Symptomatic COVID-19 Cases In The United States. *Health Aff (Millwood)*, 101377hlthaff202000455 (2020).

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

13. E. Lavezzo *et al.*, Suppression of COVID-19 outbreak in the municipality of Vo, Italy. *medRxiv*, (2020).
14. K. Mizumoto, K. Kagaya, A. Zarebski, G. Chowell, Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. *Euro Surveill* **25**, (2020).
15. D. Sutton, K. Fuchs, M. D'Alton, D. Goffman, Universal Screening for SARS-CoV-2 in Women Admitted for Delivery. *N Engl J Med* **382**, 2163-2164 (2020).
16. N. M. Linton *et al.*, Incubation Period and Other Epidemiological Characteristics of 2019 Novel Coronavirus Infections with Right Truncation: A Statistical Analysis of Publicly Available Case Data. *J Clin Med* **9**, (2020).
17. H. Rahmandad, K. Hu, Modeling the rework cycle: capturing multiple defects per task. *Syst Dynam Rev* **26**, 291-315 (2010).
18. A. Gelman, J. Hill, *Data analysis using regression and multilevel/hierarchical models*. (Cambridge university press, 2006).
19. J. A. Vrugt *et al.*, Accelerating Markov chain Monte Carlo simulation by differential evolution with self-adaptive randomized subspace sampling. *International Journal of Nonlinear Sciences and Numerical Simulation* **10**, 273-290 (2009).
20. E. Dong, H. Du, L. Gardner, An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect Dis* **20**, 533-534 (2020).
21. Z. Lipton, J. Ellignton, K. Riely. (The Atlantic).
22. Wikipedia. (2020).
23. WHO. (2020).
24. W. Bank. (2020).
25. J. Wu, A. McCann, J. Katz, E. Peltier. (2020).
26. B. Dale, N. Stylianou. (BBC, 2020).
27. N. Ghaffarzadegan, H. Rahmandad, Simulation-based Estimation of the Early Spread of COVID-19 in Iran: Actual versus Confirmed Cases. *Syst Dynam Rev* **Forthcoming**, (2020).
28. R. Verity *et al.*, Estimates of the severity of coronavirus disease 2019: a model-based analysis. *The Lancet infectious diseases*, (2020).

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Supplementary material to accompany:

Estimating the global spread of COVID-19

Contents

S1- MODEL STURCUTRE AND KEY FORMULATIONS 14
Population Groups and Transmission Dynamics 14
Modeling the Severity of Symptoms 16
Testing 17
Hospitalization 18
Infection Fatality Rates 19
Risk Perception and Responses 20
Summary of Key Equations and Parameters 21
S2- ESTIMATION METHOD 24
Overview of the Approach 24
The Fit to Time Series for Cases and Deaths 24
Incorporating the coherence of parameters across countries 25
Excess mortality penalty 26
Numerical Methods 27
S3- DATA PRE-PROCESSING 29
S4- EXTENDED RESULTS 34
Quality of fit measures 34
Estimates for true magnitude of epidemic 37
Excess deaths 37
Maximum reproduction number 39
Parameter estimates 40
Future projections 44
S5- COMPLETE MODEL DOCUMENTATION 45
S6- References 56

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

S1- MODEL STURCUTRE AND KEY FORMULATIONS

The model simulates the evolution of COVID-19 epidemic, risk perception and response, testing, hospitalization, and fatality at the level of a country. Here we explain key equations and structures in each sector, followed by complete listing of model equations and parameters in S5.

Population Groups and Transmission Dynamics

The model is a derivative of the well-known SEIR (Susceptible, Exposed, Infectious, Recovered) framework for simulating infection dynamics. Figure S5 provides an overview of key population groups and the population movements among them[1].



Figure S5- Key population stocks and flows. Rectangles represent stocks (state variables), while arrows and valves represent the flows between them (state transitions).

The *Susceptible* population (S) transitions to the *Pre-Symptomatic Infected* state (P) based on the *Infection Rate* (r_{SP}). After an average *Incubation Period* (τ_P), these pre-symptomatic infected transition into the *Infected Pre-Detection* (I_P) state. After a further average *Onset to Detection Delay* (τ_I), this group splits among multiple pathways. First, if tested positive for COVID-19, they transition into either *Infectious Confirmed Not Hospitalized* (I_C) or *Hospitalized Infectious Confirmed* (I_{CH}). Anyone not tested positive, whether for lack of testing or erroneous test results, transitions into either *Hospitalized Infectious Unconfirmed* (I_{UH}) or *Infectious Unconfirmed Post-Detection* (I_U). We assume demand for testing and hospitalization are driven by symptoms, so all asymptomatic patients will be in the latter category.

[1] In the equations below we use short-hands to simplify mathematical notations. The full model documentation uses full variable names. Table S1 provides the mapping between the short-hands and the full names, as well as the sources and equations for those variables and parameters discussed below.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

From these Infectious categories, resolution flows ($r_{...}$) take individuals to either Recovered (R...) or Dead (D...) states, with corresponding subscripts $_U$, $_C$, $_{CH}$, and $_{UH}$ for stocks and $_{UU}$, $_{UHCH}$ etc. for flows. Given the differences in severity and potential survival extension due to hospitalization, we distinguish between resolution delay for those in hospital (*Hospitalized Resolution Time;* τ_H) and those not hospitalized (*Post-Detection Phase Resolution Time*; τ_R). We use first order exponential delays for all lags, though sensitivity analyses showed very little impact of using higher order delays.

The *Infection Rate* (r_{SP}) controls the flow from S to P and depends on *Infectious Contacts* (C_I), fraction of total *Population* (N) that is susceptible, and *Weather Effect on Transmission* (W). The latter is a function of R_W, the country-level projections for impact of weather on COVID-19 transmission risk year-round developed by Xu and colleagues (*7*) and a parameter, *Sensitivity to Weather* (s_W), to be estimated:

$$r_{SP} = C_I W \left(\frac{S}{N}\right) \quad (1)$$

$$W = R_W^{s_W} \quad (2)$$

Infectious contacts depend on the *Reference Force of Infection* (β), various infectious sub-populations (and their relative transmission rates; m_a for asymptomatic and m_T for confirmed), and *Contacts Relative to Normal* (F_C), which captures behavioral and policy responses as a fractional multiplier to baseline infectious contacts:

$$C_I = \beta F_C (m_a (P^a + I_P^a + I_U^a) + I_P^s + I_U^s + P^s + I_{UH} + m_T (I_{CH} + I_C)) \quad (3)$$

In this equation we separate various stocks (of I and P) into asymptomatic (a superscript) and symptomatic (s superscript). That distinction is treated analytically using a zero-inflated Poisson distribution that is discussed in the next section. In light of evidence on the short serial interval for COVID-19, likely below the incubation period (*29, 30*), we do not distinguish the infectivity of pre-symptomatic individuals from those post onset. Contagion dynamics start from *Patient Zero Arrival Time*, T_0, another estimated parameter. The key mechanisms regulating the population flows among these stocks are discussed below, and a schematic of important relationships is provided in Figure S6.

Five parameters are estimated in the equations discussed above. One of them (s_W) is global (i.e. assumed identical across countries; see the estimation section below for details on the distinction between global and country-specific parameters) and the remaining four are country-specific: β, m_T, m_a, *and* T_0.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .



Figure S6- Overview of model's mechanisms. Major feedback loops are identified as Balancing (or Negative feedback; B) and Reinforcing (or Positive feedback; R).

Modeling the Severity of Symptoms

COVID-19 infection varies in acuity, from asymptomatic to life-threatening. Acuity of disease affects not-only baseline fatality risk, but also testing and hospitalization decisions which impact official records of infection and fatality rates. Since movement between population groups via testing or hospitalization is itself a function of acuity, to allow for consistent inference of mean acuity across different population groups, we use an analytical framework to track acuity levels. This framework, which we adapted from prior research (*17*), obviates the need to disaggregate the population by different acuity levels (which would prohibitively raise the computational costs for estimation).

Specifically, we represent acuity using a zero-inflated Poisson distribution. This distribution combines two subpopulations – one with Poisson-distributed acuity levels with mean *Covid Acuity* (α_C), and another *Additional Asymptomatic Fraction* with zero acuity, which is the zero-inflated component. The sum of those with zero acuity from the Poisson part of the population and the second group is the *Total Asymptomatic Fraction* (*a*). We assume this asymptomatic group is not given priority in testing or hospitalization, and is not at risk of death. Thus they will always follow the $S \xrightarrow{r_{SP}} P \xrightarrow{r_{PP}} I_P \xrightarrow{r_{IU}} I_U \xrightarrow{r_{UU}} R_U$ pathway. The pathways for the remaining population depend on acuity and its impacts on testing, hospitalization, and death. Note that the concept of acuity defined here only needs to have a monotonic relationship with tangible symptoms and risk factors and it does not have a one-to-one relationship with any real world measure of acuity, and as such is better seen as a mathematical construct that informs modeling rather than a real-world variable with clinical definition.

From this framework two parameters, *a* and α_C, are estimated as country specific parameters with limited variability across countries.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Testing

The testing sector reads the *Active Test Rate* (T_t) for each country as exogenous input data (see appendix S3 for pre-processing details for this data). A fraction of this total test rate, typically small, is allocated to post-mortem testing of COVID-19 victims who have not been previously confirmed (*Post Mortem Tests Total*, T_{PM}). Specifically, of the deaths of unconfirmed infectious individuals (whether hospitalized or not), a certain *Fraction of Fatalities Screened Post Mortem* (n_{PM}) will be identified true post-mortem tests. We anchor the n_{PM} to *Fraction Covid Death In Hospitals Previously Tested* (n_{DCH}). The rationale for this anchoring is that on the margin if there are many unidentified COVID patients in hospitals, the chances are that the system lacks enough testing capacity and thus post-mortem testing should also be less thorough:

$$n_{PM} = n_{DCH} \tag{4}$$

We experimented other functional forms with a free parameter connecting the two constructs, but following our conservative estimation principle decided against including that free parameter in the final model. We feared that absent clear observables to identify this additional parameter (e.g. on country-specific policies regulating post-mortem testing) the degree of freedom would improve the fit but potentially for the wrong reason.

The remaining *Testing Capacity Net of Post Mortem Tests* ($T_{Net} = T_t - T_{PM}$) is allocated to test demand from two sources. First, symptomatic COVID patients leaving the pre-detection (I_P) phase may seek testing (*Positive Candidates Interested in Testing Poisson Subset*: $M_C = \frac{I_P}{\tau_T}(1-a)$). Second, COVID-negative individuals may seek testing due to various perceived risks and other conditions with overlapping symptoms such as common cold and influenza-like illnesses (M_N, *Potential Test Demand from Susceptible Population*). This "negative" demand includes a *Baseline Daily Fraction Susceptible Seeking Tests* (n_{ST}) of the population not previously tested positively (N_U), and increases with the *Recent Detected Infections* (T_{PIR}), which is an exponentially weighted moving average of *Positive Tests of Infected* (T_{PI}). COVID-positive and COVID-negative sources of demand add up to create the overall *Testing Demand* (M_T):

$$M_N = n_{ST} N_U + m_{IT} T_{PIR} \tag{5}$$

$$M_T = M_N + M_C \tag{6}$$

Where the *Multiplier Recent Infections to Test* (m_{IT}), captures the sensitivity of negative test demand to recent infection reports.

To allocate the available tests (T_{Net}) between these two sources of demand, we use an analytical logic that allocates testing based on acuity of symptoms. The basic idea is that through self selection and screening by testing centers, people who have more symptoms or other signals that correlate with COVID infection (e.g. high exposure risk) are more likely to be tested. We assume each unit of acuity increases the likelihood that an individual gets tested, based on a variable *Prob Missing Symptom*, p_{MS}. This variable represents the probability that each acuity unit fails to convince the testing decision process to test a given individual, i.e. how selectively and sparingly tests are conducted. Specifically, in this model an individual with k acuity units is tested with probability:

$$p(test|k\ symptoms) = 1 - p(missing\ k\ symptoms) = 1 - p_{MS}^k \tag{7}$$

We assume the negative test demand is coming from a population with a Poisson-distributed, unit average acuity level (α_N=1) for symptoms of non-COVID influenza-like illnesses. The test demand from COVID

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

patients also comes from a Poisson distribution of acuity, but with mean α_C. With the Poisson distribution and given a level of α and p_{MS}, one can calculate the fraction of each demand source that would be tested:

$$p(getting\ test) = 1 - p(not\ being\ tested) = 1 - \sum_{k=0}^{k=\infty} \frac{e^{\alpha}\alpha^k}{k!} p_{MS}^k = 1 - e^{-\alpha(1-p_{MS})} \quad (8)$$

We therefore need to find the p_{MS} that allows test supply to match demand that is satisfied, specifically, by solving the following equation for p_{MS}*:

$$T_{Net} = M_N(1 - e^{-\alpha_N(1-p*_{MS})}) + M_C(1 - e^{-\alpha_C(1-p*_{MS})}) \quad (9)$$

Having solved for $p*_{MS}$ (numerically), we analytically calculate the average acuity level for those positively tested (α_{CP}: *Average Acuity of Positively Tested*) and those either not tested or having received a false negative result (α_{CN}). Specifically, if test sensitivity was 100%, the average acuity for those not tested would be:

$$\alpha_{Not\ Tested} = \sum_{k=0}^{k=\infty} k \frac{e^{\alpha}\alpha^k}{k!} {p_{MS}^*}^k = \alpha p_{MS}^* e^{-\alpha(1-p*_{MS})} \quad (10)$$

The acuity level for those tested could then be found based on the conservation of total acuity across those positively tested and those not. Starting with this basic specification we further account for the *Sensitivity of Covid Test (s_T)* to calculate the values of α_{CP} and α_{CN}. We parametrize sensitivity at 70%, which is the estimated sensitivity for the PCR-based tests used as the primary diagnosis method of current infections of COVID-19 (*4, 5*).

Overall, the testing rates that are determined by solving for p_{MS}^*, combined with sensitivity of tests, inform the fraction of COVID positive individuals transitioning from pre-detection (I_P) to confirmed vs. unconfirmed states (I_C or I_{CH} vs. I_U or I_{UH}), while the calculated α values inform the likelihood of hospitalization and fatality rates, as discussed next.

The testing sector includes the following two country level parameters that are estimated: n_{ST}, m_{IT}.

Hospitalization

The hospitalization sector of the model starts with each country's *Nominal Hospital Capacity* (h_N) in total hospital beds. In practice, geographic variation in hospital density and demand creates imperfect matching of available beds with cases of COVID-19 at any point in time, e.g. because some potential capacity is physically distant from current COVID hotspots. This imperfect matching means some of the nominal hospital capacity is effectively unavailable at any time, especially in larger, less densely populated countries. We therefore calculate *Effective Hospital Capacity* (h_E) by considering geographic density of hospital beds (*Bed per Square Kilometer; d_H*):

$$h_E = h_N \left(\frac{d_H}{d_H^*}\right)^{s_{DH}} \quad (11)$$

Where the d_H^* represents a large *Reference Hospital Density* of 6.06 beds per km^2 (which is the value of d_H for South Korea). The parameter s_{DH} (*Impact of Population Density on Hospital Availability*) is estimated.

Effective capacity is allocated between *Potential Hospital Demand* (H_{CD}) from COVID-19 cases and the regular demand for hospital beds from all other conditions (which we assume equals pre-pandemic effective hospital capacity). We assume that COVID-19 patients will have higher priority for hospitalization compared to regular demand. Specifically, we assume that fraction of regular demand allocated (m_{HR}) would be the

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

square of that for COVID demand (m_{HC}), $m_{HR} = m_{HC}^2$, and solve the resulting hospital capacity allocation problem analytically:

$$h_E = h_E m_{HR} + H_{CD} m_{HC} \Rightarrow m_{HC} = \frac{-H_{CD} + \sqrt{H_{CD}^2 + 4h_E^2}}{2h_E} \quad (12)$$

We determine the COVID demand for hospitalization based on a screening process similar to that for testing. Two types of COVID patients may seek hospitalization: those with confirmed test results and those without. The former are more likely to seek hospital treatment. We first calculate a parameter analogous to p_{MS} in the testing sector that informs the demand from confirmed COVID patients for hospitalization. This parameter, the *PMAS Confirmed for Hospital Demand* (p_{MHC}) is determined based on acuity level of confirmed (α_{CT}) and *Reference COVID Hospitalization Fraction Confirmed* (r_H), an estimated parameter capturing the overall need for hospitalization among COVID patients:

$$p_{MHC} = (1 - r_H)^{\frac{1}{\alpha_{CT}}} \quad (14)$$

For unconfirmed COVID patients we scale the analogue of this parameter (p_{MHU}) based on how much priority non-COVID patients generally receive:

$$p_{MHU} = p_{MHC} + (1 - p_{MHC})(1 - m_{HR}) \quad (15)$$

This formulation ensures that: 1) Confirmed COVID patients are more likely to be hospitalized, but also that 2) if there is ample hospital capacity (m_{HR}~1), then confirmed and unconfirmed COVID patients will receive similar priority for the same level of acuity. In short, the $p_{M.}$ values determine hospital demand by confirmed and unconfirmed COVID patients, which add up to H_{CD}. The latter determines the fraction of hospital demand that is met. Analogous to the testing sector, this fraction along with demand determines the flow of individuals from the pre-detection (I_P) state to hospitalized vs. non-hospitalized states (I_{CH} or I_{UH} vs. I_C or I_U). Matching demand to allocated capacity also allows us to calculate the realized *Probability of Missing Acuity Signal at Hospitals* (p^*_M) for confirmed and unconfirmed patients. As in the testing sector, those probabilities let us approximate for the expected acuity levels for COVID patients in and out of hospital, as well as tested vs. not-tested, i.e. α_{CT}, α_{CH}, α_U, and α_{UH}. These average acuity levels in turn inform fatality rates for each group.

The hospital sector includes two country level estimated parameter with limited variation across countries: s_{DH} and r_H.

Infection Fatality Rates

For patients in each of the $_U$, $_C$, $_{CH}$, and $_{UH}$ groups we specify the *Infection Fatality Rate* (f), as:

$$f_{(.)} = f_b \alpha_{(.)}^{s_f} s_{HF}(.) g_{Ag} \quad (16)$$

The parameter *Base Fatality Rate for Unit Acuity* (f_b) sets the baseline for fatality rate. *Sensitivity of Fatality Rate to Acuity* (s_f) determines how fatality changes with estimated acuity levels; more severe cases are expected to have higher fatality rates. Hospitalization reduces fatality rates, expressed as the relative *Impact of Treatment on Fatality Rate* (s_{HF}). The g_{Ag} function incorporates the impact of age distribution on fatality rates. For age effect, we calculate a risk factor for each country based on its age distribution and the relative fatality risks for COVID patients in different ages documented in prior work (*9*). We normalize this factor

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

against its value for China where the original study was conducted. Given the well-established impact of age on fatality, this factor is directly multiplied into the infection fatality equations.

Overall, the fatality sector includes three parameters that are estimated at the country level, with limited variance across countries, those are: f_b, s_{HF}, and s_f.

Note on comorbidities and fatality: We also explored including three comorbidities but found the estimates unreliable and therefore they are not included in the main specification of the model. Those comorbidities include obesity, chronic disease, and liver disease. The effects we explored for each were: $g_{(.)} = d_{(.)}^{s_{(.)f}}$, where we used the following country-level indicators from the World Health Organization (*23*), normalized by the average across all countries ($d_{(.)}$):

For obesity: Prevalence of obesity among adults, BMI ≥30 (age-standardized estimate) (%)

For chronic health issues: Probability (%) of dying between age 30 and exact age 70 from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease

For liver disease: Liver cirrhosis, age-standardized death rates (15+), per 100,000 population

Risk Perception and Responses

In equation 3 we noted that *Contacts Relative to Normal* (F_C) regulates infection rates. This factor ranges between a minimum (*Min Contact Fraction*; c_{Min}) and 1 as a function of the relative *Utility from Normal Activities* (U_N) compared to *Utility from Limited Activities* (U_L) in light of additional risks associated with normal activity patterns:

$$F_C = \frac{F}{F(0)}(1 - c_{Min}) + c_{Min} \tag{17}$$

$$F = \frac{U_N}{U_N + U_L} \tag{18}$$

The utilities from normal and limited activities are specified as $U_N = e^{s_C(1-L_R)}$ and $U_L = e^{0.5 s_C}$. The former depends on the *Perceived Risk of Life Loss* (L_R) while the latter depends only on the *Sensitivity of Contact Reduction to Utility* (s_C). L_R adjusts to an underlying *Indicated Risk of Life Loss* (L_R^*) with a time constant that is asymmetric, i.e. *Time to Upgrade Risk* (τ_{RU}) could be different from *Time to Downgrade Risk* (τ_{RD}). The L_R^* itself depends on *Perceived Hazard of Infection* (Z_{IP}) from pursuing normal activities, the perceived risk of loss of life in case of infection (p_D, for which we use the global ratio of cumulative deaths to cases to date); a discount rate to turn daily costs to life-long ones (γ=0.03/year); and an estimated parameter to capture variations in risk communication, policies, and risk perceptions across countries (*Dread Factor in Risk Perception*, λ):

$$\frac{dL_R}{dt} = \frac{L_R^* - L_R}{\tau_{R.}} \tag{19}$$

$$L_R^* = \frac{Z_{IP}\lambda p_D}{\gamma} \tag{20}$$

Finally, the *Perceived Hazard of Infection* (Z_{IP}) is an average of reported daily hazard of infection (with the weight *Weight on Reported Probability of Infection,* w_R) and true hazard for symptomatic infections which individuals may perceive through word of mouth and their social networks.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Overall, the risk perception and response sector includes the following five country-specific parameters that are estimated: c_{Min}, τ_{RU}, τ_{RD}, λ, and w_R.

Summary of Key Equations and Parameters

Table S1 summarizes the main equations discussed in appendix S1, providing the mapping between full variable names and the short forms. It also includes all estimated model parameters, as well as those specified based on prior research.

Table S1- Mapping between full variable names and their short form for the subset of variables and parameters discussed in S1. Also included are equations explained above and sources for other variables.

Short form	Full variable name	Equation/Source
T_t	*Active Test Rate*	Data (See S3 for pre-processing details)
m_{HC}	*Allocated Fraction COVID Hospitalized*	$\frac{-H_{CD}+\sqrt{H_{CD}^2+4h_E^2}}{2h_E}$
m_{HR}	*Allocated Fration NonCOVID Hospitalized*	m_{HC}^2
α_{CP}	*Average Acuity of Positively Tested*	See full documentation
f_b	*Base Fatality Rate for Unit Acuity*	Estimated
n_{ST}	*Baseline Daily Fraction Susceptible Seeking Tests*	Estimated
d_H	*Bed per Square Kilometer*	Data (*23*)
m_T	*Confirmation Impact on Contact*	Estimated
F_C	*Contacts Relative to Normal*	$\frac{F}{F(0)}(1-c_{Min})+c_{Min}$
α_C	*Covid Acuity*	Estimated
R_W	*CRW*	Use estimates from (*7*)
g_{AG}	*Demographic Impact on Fatality Relative to China*	Use estimates based on (*9, 23*)
γ	*Discount Rate per Day*	$8.2e^{-5}$ /Day
λ	*Dread Factor in Risk Perception*	Estimated
h_E	*Effective Hospital Capacity*	$h_N\left(\frac{d_H}{d_H^*}\right)^{s_{DH}}$
n_{DCH}	*Fraction Covid Death In Hospitals Previously Tested*	See full documentation
n_{PM}	*Fraction of Fatalities Screened Post Mortem*	n_{DCH}
I_{CH}	*Hospitalized Infectious Confirmed*	See full documentation
I_{UH}	*Hospitalized Infectious Unconfirmed*	See full documentation
τ_H	*Hospitalized Resolution Time*	20 Days
s_{DH}	*Impact of Population Density on Hospital Availability*	Estimated
s_{HF}	*Impact of Treatment on Fatality Rate*	Estimated
τ_P	*Incubation Period*	5 days
L_R^*	*Indicated Risk of Life Loss*	$L_R^* = \frac{Z_{IP}\lambda p_D}{\gamma}$
I_P	*Infected pre Detection*	See full documentation
I_U	*Infected Unconfirmed Post-Detection*	See full documentation

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

f(.)	*Infection Fatality Rate (.)*	$f_b \alpha_{(.)}^{s_f} s_{HF}(.) g_{Ag}$
r_{SP}	*Infection Rate*	$C_I W\left(\frac{S}{N}\right)$
I_C	*Infectious Confirmed Not Hospitalized*	See full documentation
C_I	*Infectious Contacts*	$\beta F_C(m_a(P^a + I_P^a + I_U^a) + I_P^s + I_U^s + P^s + I_{UH} + m_T(I_{CH} + I_C))$
c_{Min}	*Min Contact Fraction*	Estimated
m_{IT}	*Multiplier Recent Infections to Test*	Estimated
h_N	*Nominal Hospital Capacity*	Data
τ_T	*Onset to Detection Delay*	5 Days
T_0	*Patient Zero Arrival Time*	Estimated
Z_{IP}	*Perceived Hazard of Infection*	See full documentation
L_R	*Perceived Risk of Life Loss*	$\frac{dL_R}{dt} = \frac{L_R^* - L_R}{\tau_R}$
N	*Population*	Data (*24*)
M_C	*Positive Candidates Interested in Testing Poisson Subset*	$\frac{I_P}{\tau_T}(1-a)$
T_{PM}	*Post Mortem Tests Total*	See full documentation
τ_R	*Post-Detection Phase Resolution Time*	10 Days
H_{CD}	*Potential Hospital Demand*	See full documentation
M_N	*Potential Test Demand from Susceptible Population*	$n_{ST} N_U + m_{IT} T_{PIR}$
T_{PI}	*Positive Tests of Infected*	See full documentation
P	*Pre-Symptomatic Infected*	See full documentation
p_{MHC}	*PMAS Confirmed for Hospital Demand*	$(1 - r_H)^{\frac{1}{\alpha c}}$
p_{MHU}	*PMAS Unconfirmed for Hospital Demand*	$p_{MHC} + (1 - p_{MHC})(1 - m_{HR})$
p_{MS}	*Prob Missing Symptom*	From solution to equation 9
p_D	*PseudoCFR*	Data
T_{PIR}	*Recent Detected Infections*	See full documentation
r_H	*Reference COVID Hospitalization Fraction Confirmed*	Estimated
β	*Reference Force of Infection*	Estimated
d_H^*	*Reference Hospital Density*	Data (*23*)
m_a	*Multiplier Transmission Risk for Asymptomatic*	Estimated
s_T	*Sensitivity of Covid Test*	0.7
s_f	*Sensitivity of Fatality Rate to Acuity*	Estimated
s_C	*Sensitivity of Contact Reduction to Utility*	Estimated
s_W	*Sensitivity to Weather*	Estimated
S	*Susceptible*	See full documentation
T_{Net}	*Testing Capacity Net of Post Mortem Tests*	$T_t - T_{PM}$
M_T	*Testing Demand*	$M_N + M_C$
τ_{RD}	*Time to Downgrade Risk*	Estimated
τ_{RU}	*Time to Upgrade Risk*	Estimated

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

a	*Total Asymptomatic Fraction*	Estimated
U_L	*Utility from Limited Activities*	$e^{0.5sc}$
U_N	*Utility from Normal Activities*	$e^{sc(1-L_R)}$
w_R	*Weight on Reported Probability of Infection*	Estimated
W	*Weather Effect on Transmission*	R_W^{sw}

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

S2- ESTIMATION METHOD

Overview of the Approach

The model we estimate is nonlinear and complex, and any estimation framework is unlikely to have clean analytical solutions or provable bounds on errors and biases. Therefore, in designing our estimation procedure, we set out to be conservative. Specifically: we use a likelihood function that accommodates overdispersion and autocorrelation (negative binomial); we utilize a hierarchical Bayesian framework to couple parameter estimates across different countries which reduces the risk of over-fitting the data; and we use the conceptual definitions of parameters and their expected similarity across countries to inform the magnitude of that coupling across countries. Compared to more common choices in similar estimation settings, these choices tend to widen the credible regions for our estimates and reduce the quality of the fit between model and data. In return, we think the results may be more reliable for projection, more informative about the underlying processes, and better reflective of uncertainties in such complex estimation settings.

The model is a deterministic system of ordinary differential equations with a set of known and unknown parameters. The known parameters are those specified based on the existing literature and do not play an active role in estimation. The unknown parameters can be categorized into those that vary across different countries and those that are the same across all countries (i.e. general parameters). The estimation method is designed to identify both the most likely value and the credible regions for the unknown parameters, given the data on reported cases and deaths (and for a subset of countries, the excess deaths). This is done through a combination of estimating the most likely parameter values in a likelihood based framework, and using Markov Chain Monte Carlo simulations to quantify the uncertainties in parameters and projections.

We first introduce the 3 different components of the likelihood function we use: the fit to time series data, the random effects component coupling country-level parameters, and the penalty for excess mortality. Then we explain the implementation details.

The Fit to Time Series for Cases and Deaths

Define model calculations for expected reported cases and deaths for country i as $\mu_{ij}(t)$ (with index j specifying cases and deaths) and the observed data for those variables as $y_{ij}(t)$; the country-level vector of unknown parameters as $\boldsymbol{\theta_i}$ and the general unknown parameters as $\boldsymbol{\phi}$. Note that $\boldsymbol{\theta_i}$ vector includes several parameters, each specifying an unknown model parameter, such as Impact of Treatment on Fatality, or Total Asymptomatic Fraction, for country i. The model can be summarized as a function f that produces predictions for expected cases and deaths for each country given the general and country-specific parameters:

$$\mu_{ij}(t) = f(\boldsymbol{\phi}, \boldsymbol{\theta_i}) \tag{21}$$

We use a negative binomial distribution to specify the likelihood of observing the y values given $\boldsymbol{\theta}$ and $\boldsymbol{\phi}$. Specifically, the logarithm of likelihood for observing the data series y given model predictions $\mu(\boldsymbol{\theta}, \boldsymbol{\phi})$ is:

$$LT(t|\boldsymbol{\phi}, \boldsymbol{\theta}) = \sum_{ij} L1_{ij}(t) + L2_{ij}(t) + L3_{ij}(t) \tag{22}$$

where (dropping time index for clarity):

$$L1_{ij} = -\sum_{y_{ij}=0} \frac{\ln(1+\varepsilon_i \mu_{ij})}{\varepsilon_{ij}} \tag{23}$$

$$L2_{ij} = \sum_{y_{ij}>0} \sum_{k=0}^{y_{ij}-1} \ln\left(k + \frac{1}{\varepsilon_{ij}}\right) \tag{24}$$

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

$$L3_{ij} = \sum_{y_{ij}>0}[-\ln(y_{ij}!) - \left(y_{ij} + \frac{1}{\varepsilon_{ij}}\right)\ln(1+\varepsilon_{ij}\mu_{ij}) + y_{ij}\ln(\varepsilon_{ij}) + y_{ij}\ln(\mu_{ij}) \quad (25)$$

Summing the LT function over time provides the full (log) likelihood for the observed data given a parameterization of the model. The negative binomial likelihood function includes two parameters, μ and ε which determine the mean and the scaling/shape of the observed outcomes. The second parameter, ε, provides the flexibility needed fit outcomes with fat tails and auto-correlation. This parameter could itself be subject to search in the optimization process. Specifically, we assume that:

$$\varepsilon_{ij} = \varepsilon_i \varepsilon_j \quad (26)$$

Thus we create a (set of) country specific parameter(s) (ε_i) and two general parameters (ε_j) which should be estimated along with the conceptual model parameters. The country level scale (ε_i) implicitly assesses the reliability and inherent variability in country level reports, and the general ones inform the variability in case data vs. deaths. We augment the vectors $\boldsymbol{\phi}$ and $\boldsymbol{\theta}$ to include these scaling parameters as well.

Incorporating the coherence of parameters across countries

Up to this point we have not included any relationship among country specific parameters, $\boldsymbol{\theta_i}$. This independence assumption would allow parameters representing the same underlying concept to vary widely across different countries. Such treatment, by providing more flexibility, enhances the model's fit to historical data. However, it ignores the conceptual link that exists for a given parameter across countries, potentially allowing the model to fit the data for the wrong reasons (i.e. using parameter values that do not correspond to meaningful real world concepts). The result would likely be less reliable and also not robust for future projections. We therefore define a Hierarchical Bayesian framework to account for the potential dependencies among model parameters. Specifically, we assume the same conceptual parameters (e.g. Impact of Treatment on Fatality), across different countries, are coming from an underlying normal distribution with an unknown mean (to be estimated) and a pre-specified standard deviation. This assumption is similar to the use of "Random Effect" models common in regression frameworks, though we deviate from canonical random effect models by pre-specifying the standard deviation. In fact it is possible to estimate the standard deviation across countries as well (and to obtain better fits to data), but adding those degrees of freedom ignores qualitatively relevant insights about the level of coupling across different countries for each parameter, and thus results may fit the data better but for the wrong reasons. For example, some parameters, such as Patient Zero Arrival Time, could be very different across countries, whereas parameters reflecting innate properties of the SARS-CoV-2 virus itself (e.g. *Total Asymptomatic Fraction* (*a*)) or those determining fatality (e.g. *Base Fatality Rate for Unit Acuity* (f_b)) should be very similar across different countries. Allowing the model to determine the variance for the latter will lead to better fits: the model can find baseline fatality rates that easily match fatality variations across countries, and would expand the corresponding variance parameter accordingly. However, as a result the estimation algorithm will have too easy a job: it will not require a precise balancing between hospitalization, impact of acuity on fatality, and post-mortem testing decisions to fit fatality data. Thus, the estimates may well be less informative, or further from true underlying processes and the general characteristics of the disease which we care about. The implementation of this random effect introduces another element to the overall likelihood function:

$$LC(\boldsymbol{\theta}) = -\sum_{ik} \frac{(\theta_{ik} - \bar{\theta}_k)^2}{2\sigma_k^2} \quad (27)$$

Here θ_{ik} represents the kth parameter for country i, and $\bar{\theta}_k$ is the (estimated) average across countries for the kth parameter. σ_k is the pre-specified allowable variability for the kth parameter across different countries.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Specifying these standard deviations adds a subjective element to the estimation process. However, we note that subjective elements are ultimately indispensable in any modeling activity: from specifying the model boundary to the level of aggregation, use of various functional forms, and choice of likelihood functions, these choices are built on subjective assessments that experts bring to a modeling project. Absent our conceptually informed variability factors, we would need to make the assumption that country-level parameters are independent, or that our complex estimation process would correctly identify the true dependencies among those parameters. We think both those alternatives are inferior in the chosen method. So here we focus on transparently documenting and explaining those assumptions. Table S2 summarizes the estimated model parameters, their estimated values (mean across countries and mean of Inter-Quartile Range) and the assumed variability factor (σ_k) for each.

Table S2- Estimated model parameters, their estimated values (mean and standard deviation (std) across countries and the mean of Inter-Quartile Range (MIQR). Last column reports the variability allowances used to specify the coupling among country-level estimates. See equation 27 and related discussions above.

Parameter Name		**Mean**	**StDev**	**MIQR**	**Variability Factor, σ_k**
f_b	*Base Fatality Rate for Unit Acuity***	5.50e-04	4.65e-06	1.21e-05	$1e^{-5}$
n_{ST}	*Baseline Daily Fraction Susceptible Seeking Tests*	9.00e-04	8.93e-04	3.02e-04	0.0005
m_T	*Confirmation Impact on Contact*	1.18e-01	2.27e-02	1.10e-01	0.1
α_C	*Covid Acuity***	5.90e+00	8.52e-04	1.22e-02	0.01
λ	*Dread Factor in Risk Perception**	4.19e+02	6.71e+02	5.84e+02	$10^{0.8}$
s_{DH}	*Impact of Population Density on Hospital Availability*	2.78e-01	1.04e-01	1.12e-01	0.1
s_{HF}	*Impact of Treatment on Fatality Rate*	3.95e-01	1.78e-01	7.88e-02	0.1
c_{Min}	*Min Contact Fraction*	1.70e-02	1.15e-02	2.34e-02	0.03
m_{IT}	*Multiplier Recent Infections to Test*	5.52e+01	4.16e+01	2.15e+01	30
m_a	*Multiplier Transmission Risk for Asymptomatic***	2.80e-01	6.78e-03	2.42e-02	0.02
β	*Reference Force of Infection*	4.50e-01	1.74e-01	1.24e-01	0.2
r_H	*Reference COVID Hospitalization Fraction Confirmed*	2.07e+00	1.69e-03	6.08e-03	0.1
s_f	*Sensitivity of Fatality Rate to Acuity***	6.56e+00	4.64e+00	2.12e+00	0.005
s_C	*Sensitivity of Contact Reduction to Utility*	7.00e+01	3.12e+01	4.92e+01	6
τ_{RD}	*Time to Downgrade Risk**	1.13e+01	7.07e+00	3.83e+00	$10^{0.3}$
τ_{RU}	*Time to Upgrade Risk**	5.50e-01	5.97e-03	3.68e-02	$10^{0.2}$
a	*Total Asymptomatic Fraction ***	8.35e-01	1.12e-01	1.55e-01	0.03
w_R	*Weight on Reported Probability of Infection*	4.50e-01	1.74e-01	1.24e-01	0.2
s_W	*Sensitivity to Weather*	*0.765 (global parameter so the other metrics do not apply)*			

**Given the wide range and potential long tail for these parameters the Log_{10} transformation is used in specifying the dispersion penalty (equation 27) and variability factors are reported as 10^{σ}, where σ is used in equation 27.*
*** These parameters are expected to be less variable across countries and thus are assigned small variability allowances compared to their mean.*

Excess mortality penalty

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Finally, we include a likelihood-based penalty term to allow model predictions be informed by excess mortality data collected by various news agencies and researchers for a subset of countries in our sample. These data provide snapshots of excess mortality (compared to a historical baseline) for a window of time in each country. Subtracting from total excess mortality the COVID-19 deaths officially recorded in that window offers a data point for excess mortality not accounted for in official data (e_i). We can calculate in the model the counter-part for this construct: the simulated mortality that is not included in the simulated reported COVID-19 deaths ($\bar{e}_i$). There is uncertainty in these excess mortality data: the historical baselines used by various sources do not adjust for demographic change, excess mortality may be due to factors other than COVID-19, and some of it may be due to changes in healthcare availability and utilization motivated by COVID-19 but not directly attributable to the disease (for example when surgeries are delayed, hospitalization is avoided, or heart conditions are ignored). Excess mortality may also be reduced due to reduced traffic accidents (in light of physical distancing policies) and pollution related deaths. Given these uncertainties, we use the following penalty function to keep the simulated unaccounted excess mortality close to data:

$$LE = -\sum_i \left(\frac{0.9e_i - \bar{e}_i}{0.2e_i}\right)^4 \tag{28}$$

This penalty could be seen as a likelihood coming from the probability distribution $p(x) = \frac{\exp^{-x^4}}{1.8128}$ defined for all values of *x*. It assumes that in the most likely case for excess mortality, 90% of unaccounted mortality should be attributed to COVID-19 deaths, but that there is significant uncertainty around this, so some 20% variation across this figure is quite plausible (70%-110% of data). However, numbers outside of this range start to impose increasingly large penalties, so that very large deviation becomes unlikely.

Combining these three components, we obtain the full likelihood function used in the analysis:

$$LL = LC + LE + \sum_{t=t_0}^{t=T} LT(t) \tag{29}$$

For each country we include the LT component from the first day they have reached 0.1% of their cumulative cases to-date, or a minimum of 50 cumulative cases. This excludes very early rates that are both unreliable and which, given very small estimated model predictions for infection, could lead to unreasonably large likelihood contributions.

Numerical Methods

The model includes a large number of parameters to be estimated: a general parameter for the impact of weather, 2 general parameters for ε_j, and 21 parameters for each country that are coupled together based on the random effects framework described above. Out of those 1 parameter is for ε_i and the rest are informing various features of disease transmission, testing, hospitalization, and risk perception and response. With a sample of 84 countries, this would lead to about 1800 parameters to be estimated. A direct optimization approach to this problem suffers from potential risk of getting stuck in local optima, and direct use of MCMC methods to find the promising region of parameter space suffers from the curse of dimensionality. We therefore designed the following 4-step procedure to find more reliable solutions to both problems.

1) We estimate the model with the full parameter vector for a smaller number of countries with larger outbreaks (3-5 countries). We use the Powell direction search method implemented in Vensim™ simulation software for this step. The method is a local search approach though it has features that allows it to escape local optima in some cases. We restart the optimization from various random points in the feasible parameter space and track the convergence of those restarts to unique local peaks. We stop this process when we are repeatedly landing on the same local peaks in the parameter

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

space. This procedure showed that local peaks do exist, but they are not many; for example within 100 restarts we may find 2-4 distinct peaks. This provides a coherent set of starting points for $\boldsymbol{\phi}$ and $\overline{\boldsymbol{\theta}}$ for next steps.

2) We go through iterations of the following two steps: A) Conduct country-specific optimizations with 50 restarts to find the vector of $\boldsymbol{\theta}_i$ given the $\boldsymbol{\phi}$ and $\overline{\boldsymbol{\theta}}$ from first optimization or from the step B. B) Conduct a global optimization, including all countries but fixing $\boldsymbol{\theta}_i$ and optimizing on $\boldsymbol{\phi}$ (and $\overline{\boldsymbol{\theta}}$; though that is simply the mean across country level parameters from previous round). We stop when iterations offer little improvement from one round to the next (less than 0.05% improvement in log-likelihood).
3) We conduct a full optimization allowing all parameters ($\boldsymbol{\theta}_i$, $\boldsymbol{\phi}$ and $\overline{\boldsymbol{\theta}}$) to change, starting from the point found in the last iteration of step 2. This step finds the exact peak on the likelihood landscape which is the best-fitting parameter set for the model.
4) For the MCMC, theoretically one should conduct the sampling from all model parameters in the full model. However, our experiments showed that the large dimensionality of the parameter space requires an infeasible number of samples to achieve adequate mixing and ensure reliable credible regions for parameters and projections. To overcome this challenge we note that the parameters of different countries are connected to each other only through $\boldsymbol{\phi}$ and $\overline{\boldsymbol{\theta}}$, and these general parameters are rather insensitive to dynamics in each country. The insensitivity is due to the fact that a single country only contributes about 1% to the general parameters' values, and within a typical MCMC the country-level parameters often can't change more than 10% before the resulting samples become highly unlikely. Therefore, one can conduct an approximate country-level MCMC by fixing the general parameters at those from step 3, and only sampling from the $\boldsymbol{\theta}_i$ for each country. The MCMC algorithm used is one designed for exploring high dimensional parameter spaces using differential evolution and self-adaptive randomized subspace sampling (*19*). Using this method we obtain good mixing and stable outcomes (Robin-Brooks-Gelman PSFR convergence statistic remaining under 1.1) after about 600,000 samples (the burn-in period). We continue the MCMC for each country for 1 million samples and then randomly take a subsample of those points after the burn-in period for the next step.
5) The resulting subsamples for different countries from step 4 are assembled together to create a final sample of parameters for the full model to conduct projections and sensitivity analysis at the global scale. Uncertainties in the handful of global parameters is not identified in this procedure, but can be quantified by assessing the sensitivity of the global likelihood surface to changes in those parameters.

The process above is automated using a Python script that controls the simulation software (Vensim). We conduct the analysis using a parallel computing feature of Vensim on a Windows server with 48 cores. After compiling the simulation model into C++ code (which speeds up calculations significantly), and using a simulation time step of 0.25 days, it takes about 20 hours to complete the estimation for 84 countries. Full analysis code is available online at https://github.com/tseyanglim/CovidGlobal.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

S3- DATA PRE-PROCESSING

Getting contemporaneous, comprehensive, national-level data on Covid-19 is a challenge. The most widely-cited data aggregators, such as the Johns Hopkins Center for Systems Science and Engineering's COVID-19 database (*31*), OurWorldInData portal (*3*), and the US-focused COVID Tracking Project (*21*), get their data from the same few official sources, such as the US Centers for Disease Control and Prevention (CDC), the European CDC (ECDC), and the World Health Organization (WHO). These official agencies in turn get their data from national and subnational public health authorities, which ultimately rely on reports from hospitals, clinics, and private and public health labs.

As a result, idiosyncrasies in the ground-level data collection processes permeate virtually all sources of aggregate data. Most notably, data collection involves time lags, which can differ from source to source. Daily death counts could reflect the date of actual death or the date a death is registered or reported; different UK government sources, for instance, use each of these metrics.[2] Daily infection or case counts could include the total new cases reported *on* a given date, or the total cases confirmed *from* that date; the latter would result in some 'backfill' whereby case counts for previous days can continue to increase for some time as delayed confirmations come in. Daily counts of tests conducted could report samples collected, samples processed, results reported, or a mix of these; the US CDC, for instance, reports a mix of testing by date of sample collection and date of sample delivery to the CDC.[3] Aside from differences in unit of measure (people vs. tests vs. samples), there may be different time lags involved as well. In addition to these idiosyncrasies, testing data in particular is also patchy for many countries, even as testing has become more widespread. The WHO does not report country-by-country testing, nor does the JHU Covid map outside the US. Furthermore, there are sometimes irregular delays in the reporting of test results, which can create occasional unexpected spikes in reported numbers of tests, infections, or both.[4]

Depending on the specifics of how daily infection and test counts are reported, there can in some cases be a disjunction between the two. Because confirmed case counts largely depend on positive test results, test and infection counts should be correlated – *ceteris paribus*, a day with a lot of samples collected for testing should see more confirmed cases attributed to it, while a day with no sample collection should see no cases. But since cases may not be reported by the date of the test, and tests may not be reported by the date of sample collection, officially reported numbers can get out of sync in either direction.

This problem is most salient when there are clear weekly cycles in daily rates. In most of the world, particularly western countries, daily test rates are far lower on weekends than during the week. As a result, infection numbers show a clear weekly cyclical component as well. But the weekly cycles in testing and infection numbers for a given country do not always line up. Our model explicitly accounts for the effect of testing on reported infections, but we do not explicitly model the country-level idiosyncrasies of reporting and how they vary between test data and infections. Instead we account for any such lags in pre-processing of the data to align testing and case data.

The weekly cycle occurs in many countries' death rate data as well, where it presents a different problem. A weekly cycle in testing is a behaviourally realistic part of the data-generation process, as many labs, clinics, or other testing sites for instance may be closed on weekends. As testing provides the window on the state of confirmed infections, a comparable cycle in confirmed cases is to be expected as well. By linking case confirmations to testing, our model explicitly accounts for this limited visibility on the true state of the epidemic. However, a weekly cycle in death rates almost certainly reflects different limitations of the data-

[2] https://blog.ons.gov.uk/2020/03/31/counting-deaths-involving-the-coronavirus-covid-19/
[3] https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/previous-testing-in-us.html
[4] See e.g. https://www.wcvb.com/article/massachusetts-coronavirus-reporting-delay-due-to-quest-lab-it-glitch/32288903#

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

generation process, typically to do with hospital staffing,[5] which we do not explicitly model. As such we need to address any weekly cycle in death rates through data pre-processing as well.

To deal with these challenges, we developed a multi-step algorithm to pre-process our data before feeding it into the model for calibration. The algorithm is described below. It was implemented in Python, largely using the Pandas and NumPy packages, and the code is available in full at: https://github.com/tseyanglim/CovidGlobal.

The algorithm proceeds country-by-country, following these steps on each country.

1) Examine daily cumulative test data; if data are insufficient (6 or fewer data points), drop country from the dataset.

2) Interpolate any missing daily cumulative test data points using a piecewise cubic Hermite interpolating polynomial (PCHIP) spline. If the first reported infection is before the first reported cumulative test, also extrapolate cumulative tests back to the date of first reported infection.
   a. Extrapolation to the date of first reported infection is necessary since both in the model and, to a large extent, in reality, reported infections require testing for confirmation.
   b. PCHIP spline interpolation yields a continuous monotonic function with a continuous first derivative, thus avoiding generating any anomalous rapid change in daily test rate.
   c. We used the implementation of PCHIP interpolation from the widely used SciPy package for Python.[6]

3) Calculate daily test rate as daily cumulative tests less the preceding day's cumulative test total:

$$TestRate_t = CmltTest_t - CmltTest_{t-1} \tag{30}$$

4) Examine the original daily cumulative test data to estimate how much of the calculated daily test rate is based on interpolated vs. original data.
   a. Daily test rates calculated based on mostly original data should be expected to include any weekly cycles or occasional irregularities that would also be reflected in daily infection counts. Conversely, daily test rates calculated from cumulative test counts that are largely interpolated would not be expected to fully reproduce any such cycles or irregularities, since the interpolation produces a relatively smooth function.
   b. As a rule of thumb, we examine the cumulative test data for the second half of the time from the first test to the latest test. If fewer than half the days in that window have original cumulative test data, we consider the test data to be 'sparse', requiring further processing.

[5] It may be argued that there are weekly cycles in large-scale human behaviour that may drive some true weekly cyclicality in the true rates of infection and death, and as such it may be wrong to consider such cycles to be artefacts of the data-generation process. However, we find this unlikely for a few reasons. First, weekly cycles in human interactions, largely driven by the work and school week and weekend, will have been significantly attenuated by widespread adoption of social distancing measures around the world. Second and more importantly, variation in incubation period and time before development of symptoms means that any true cyclicality in the timing of initial infection will be further attenuated in the timing of symptom development. By the same logic, wide variability in the delay from symptom development to death means there should be minimal cyclicality, if any, in the timing of deaths, meaning any such cycles visible in the data are due to measurement and reporting lags.

[6] https://docs.scipy.org/doc/scipy/reference/generated/scipy.interpolate.PchipInterpolator.html

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

5) If the test data are not sparse, account for any potential lag or other reporting delay differences between daily test rate and daily infection rate using a time-shift algorithm to estimate any such lags or delays from the data and shift the test rate time series accordingly. The time-shift algorithm ensures that any weekly cycles present in the daily infection rate data are reflected in the daily test rate data and aligned as best as possible on date, thereby accounting for the fact that model-generated reported infections depends on testing but with no time lag between test and result.
   a. First, identify the weekly component of the time series of daily infection rate and daily test rate using a seasonal-trend decomposition based on LOESS (STL) procedure.[7]
      i. STL deconstructs time series data into several components, including a trend and a seasonal component over a specified period (weekly, in this case) as well as a residual. STL is an additive decomposition, and has the advantage of allowing the seasonal component to change over time (rather than being a fixed pattern repeated exactly across the whole time series).
      ii. We used the STL implementation from the Statsmodels package for Python.[8]
   b. Shift the time series over a one-week range (from -2 to +4 days of lag between test and infection reporting), calculating the cross-correlation between the weekly seasonal component of the daily infection rate data and the daily test rate data for each time shift.
   c. Identify the time shift within this range that maximizes the cross-correlation between the infection rate and test rate data, and shift the test rate data accordingly.

6) If the test data are sparse, the spline interpolation will generally cut out some of any weekly cyclicality that may be present. Visual inspection of daily test rates for countries with sparse test data also shows large, irregular spikes in reported tests are not uncommon, without necessarily having concomitant irregular spikes in reported daily infection rates. As such, rather than attempting to eliminate differences in reporting lags through the time-shift algorithm described above, we instead apply a data-smoothing algorithm to both daily test rate and daily infection rate, in order to reduce any cyclicality and irregular spikes. This smoothing allows the calibration of the main model to focus on matching the underlying trends in the data.

7) In all cases, whether daily cumulative test data are sparse or not and whether infection and test rate data are smoothed or not, since weekly cycles in death data are reflective of reporting lags not captured in the model, daily death rate data is smoothed using the same algorithm.

8) The smoothing algorithm used is designed first to conserve the total number of reported cases (tests, infections, or deaths), and second to preserve some degree of variation in the time series, as some noise may be informative and retaining some is important to the calibration of the model.
   a. Starting from when the time series of daily rate (test or infection) exceeds a specified minimum value (5/day), calculate the rolling mean of the daily rate, using a centred moving window of 11 days.
   b. Calculate the residual between each day's data point and the rolling mean for that day, and divide by the square root of the rolling mean, to get an adjusted deviation value:

$$AdjDev_t = \frac{Value_t - RollMean_t}{\sqrt{RollMean_t}} \tag{31}$$

      i. Dividing by the square root of the rolling mean reflects a heuristic assumption that each daily rate (of infections, deaths, or tests) behaves as a Poisson process (StDev of Pois(λ) = $\lambda^{0.5}$).

[7] Cleveland R.B., Cleveland W.S., McRae J.E., Terpenning I. (1990) STL: A seasonal-trend decomposition procedure based on Loess. *J Off Stat* 6: 3-73
[8] https://www.statsmodels.org/stable/generated/statsmodels.tsa.seasonal.STL.html

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

ii. The functional result of this adjustment is that both *absolute* and *relative* magnitudes of deviations from the rolling mean are given some weight – large relative deviations when absolute values are small (and data are noisier) are not ignored, but neither do they outweigh larger absolute (but smaller relative) deviations that occur when the mean is large, which is important since most of the time series data are growing significantly over the time horizon of the model.

c. Calculate thresholds for identifying dips and peaks in the data based on the median of the adjusted deviations, ± one median absolute deviation (MAD) of the adjusted deviations:

$$Threshold = \widetilde{AdjDev} \pm Med\left(\left|AdjDev_i - \widetilde{AdjDev}\right|\right) \quad (32)$$

i. Using the median absolute deviation to determine thresholds for peaks and dips is robust to outliers in the deviations, which do arise occasionally in the data.

ii. A threshold width of one MAD is relatively narrow for outlier detection, but by inspection of the data, is about right for identifying most of the peaks and dips caused by weekly cycles in test, infection, and death rates, as well as larger outliers.

d. Once thresholds are calculated, iterate through the data points in the time series first forward in time from oldest to newest, filling in any 'dips' (data points with adjusted deviations below the lower threshold), then backward in time from newest to oldest, smoothing out any 'peaks' (data points with adjusted deviations above the upper threshold) that remain. Repeat the process until all data points' adjusted deviations are within the originally calculated thresholds for the time series.

i. We infer that the underlying processes generating dips and peaks are somewhat different. Dips are generally the result of weekly cycles in the data, e.g. lower rates of testing or longer lags in death reporting that occur on weekends. Peaks arise to some extent due to the same weekly processes, e.g. some deaths that occur on weekends only being recorded at the start of the next week. However, some peaks, especially larger ones, may result from irregular random delays in reporting, such as large batches of tests being held up due to logistical issues and then getting processed all at once. As such the smoothing procedure for dips vs. peaks is slightly different.

e. The dip-filling step fills a fraction of each dip (specified as a *smoothing factor*) by redistributing data counts based on a multinomial draw from the subsequent few days following each dip.

i. First, calculate the amount to fill based on the deviation and the smoothing factor specified, in this case 0.67:

$$FillAmt_t = SmFactor \times (RollMean_t - Value_t) \quad (32)$$

ii. Calculate the amount redistributed from each of the following few (7) days $X_{t+1}, X_{t+2}, \ldots X_{t+k}, k = 7$, based on a multinomial distribution as follows:

$$X_{t+1}, X_{t+2}, \ldots X_{t+7} = Multinomial(FillAmt_t; p_{t+1}, p_{t+2}, \ldots\ p_{t+7}) \quad (33)$$

Where $p_{t+1}, p_{t+2}, \ldots\ p_{t+7}$ are calculated as:

$$p_{t+i} = \frac{AdjDev_{t+i} - AdjDev_t, min.0}{\sum_1^7 (AdjDev_{t+i} - AdjDev_t, min.0)} \quad (34)$$

iii. This formulation allows some redistribution from any of the subsequent few days whose adjusted deviations exceed the focal day's adjusted deviation, but with more redistribution from days with higher adjusted deviations.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

f. The peak-smoothing step similarly redistributes a fraction of each peak, specified by the smoothing factor, to the *preceding* several days based on another multinomial draw.
   i. First, calculate the amount to redistribute similarly to the dip-filling step:

$$DistAmt_t = SmFactor \times (Value_t - RollMean_t) \tag{35}$$

   ii. Calculate the amount redistributed *to* each of the preceding several (14) days $Y_{t-1}, Y_{t-2}, \dots Y_{t-k}, k = 14$, based on a multinomial distribution as follows:

$$Y_{t-1}, Y_{t-2}, \dots Y_{t-14} = Multinomial(DistAmt_t; p_{t-1}, p_{t-2}, \dots\ p_{t-14}) \tag{36}$$

   Where $p_{t-1}, p_{t-2}, \dots\ p_{t-14}$ are calculated as:

$$p_{t-i} = \frac{RollMean_{t-i}}{\sum_1^{14} RollMean_{t-i}} \tag{37}$$

   iii. This formulation redistributes peaks to preceding days based on the calculated rolling mean counts of those days, on the assumption that the irregular delays that generate random spikes in counts are essentially random and equally likely to affect any given unit of data over a several-day span. As such, the probability that a unit showing up in a spike due to such delays comes from a given preceding day is simply proportional to the expected count for that day, as approximated by the rolling mean.

g. By filling dips first before smoothing peaks, the combined algorithm largely addresses any peaks that are due primarily to weekly cycles during the dip-filling stage, such that remaining peaks that get smoothed tend to be the larger, irregular ones.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

S4- EXTENDED RESULTS

Quality of fit measures

Table S3 reports two quality of fit metrics for different countries and different time series. The first four columns report Mean Absolute Error Normalized by Mean (MAEN) and the last four report the R-Squared measures. Errors for cumulative infection and deaths are followed by those for the new cases and deaths (flow variables).

Table S3- Measures of fit between data and simulations for different countries. Mean Absolute Error Normalized by Mean (MAEN) and R-Squared are reported for cumulative and new cases and deaths.

	MAEN				R-Squared			
	Cumulative		Flow		Cumulative		Flow	
Country	Infection	Death	Infection	Death	Infection	Death	Infection	Death
Albania	0.0953	0.172	0.35	1.27	0.975	0.906	0.178	0.162
Argentina	0.159	0.0474	0.373	0.181	0.966	0.998	0.861	0.875
Armenia	0.0792	0.121	0.217	0.408	0.995	0.991	0.873	0.758
Australia	0.0939	0.0458	0.297	0.864	0.992	0.994	0.845	0.363
Austria	0.0675	0.0442	0.464	0.3	0.98	0.998	0.538	0.855
Azerbaijan	0.102	0.165	0.251	0.544	0.984	0.985	0.923	0.625
Bahrain	0.103	0.351	0.308	0.955	0.998	0.939	0.833	0.426
Bangladesh	0.0717	0.0726	0.146	0.165	0.999	0.998	0.942	0.929
Belarus	0.16	0.0663	0.186	0.22	0.999	0.996	0.844	0.764
Belgium	0.477	0.405	0.59	0.408	0.993	0.987	0.741	0.924
Bolivia	0.0725	0.0712	0.272	0.203	0.999	0.999	0.822	0.91
Bosnia	0.0709	0.0784	0.506	0.715	0.993	0.982	0.0803	0.102
Bulgaria	0.0812	0.0236	0.496	0.676	0.994	0.999	0.196	0.0787
Canada	0.91	0.15	0.824	0.18	0.992	0.999	0.703	0.849
Chile	0.168	0.12	0.369	0.301	0.99	0.99	0.43	0.785
Colombia	0.0955	0.0751	0.412	0.242	0.992	0.992	0.491	0.848
CostaRica	0.305	0.483	0.54	2.07	0.917	0.916	0.196	0.000106
Croatia	0.133	0.101	0.404	0.775	0.992	0.993	0.741	0.285
Cuba	0.107	0.207	0.331	0.764	0.998	0.974	0.663	0.467
Denmark	0.1	0.0474	0.33	0.279	0.999	0.998	0.663	0.79
Ecuador	0.147	0.11	0.796	0.354	0.983	0.994	0.0677	0.673
ElSalvador	0.104	0.0834	0.216	0.859	0.998	0.995	0.822	0.26
Estonia	0.0298	0.177	0.492	1.07	0.999	0.99	0.57	0.206
Ethiopia	0.431	0.342	0.505	0.834	0.991	0.893	0.853	0.471
Finland	0.181	0.0675	0.396	0.39	0.998	0.996	0.6	0.724
France	0.34	0.291	0.418	0.288	0.997	0.996	0.875	0.966
Germany	0.0587	0.0163	0.234	0.145	0.988	1	0.896	0.953
Ghana	0.0681	0.293	0.739	1.27	0.993	0.975	0.229	0.0419
Greece	0.053	0.0589	0.611	0.621	0.996	0.996	0.309	0.396
Hungary	0.109	0.0724	0.385	0.206	0.999	0.999	0.542	0.843
Iceland	0.0571	0.248	0.331	1.85	0.998	0.92	0.823	0.0241
India	0.166	0.0541	0.181	0.261	0.997	0.988	0.954	0.569
Indonesia	0.137	0.0492	0.392	0.229	0.992	0.996	0.457	0.677
Iran	0.0813	0.0588	0.345	0.216	0.989	0.992	0.144	0.655
Ireland	0.036	0.03	0.153	0.177	0.998	0.999	0.952	0.941
Israel	0.0852	0.0379	0.373	0.363	0.993	0.998	0.624	0.798
Italy	0.0367	0.0203	0.15	0.108	0.998	0.999	0.937	0.965
Japan	0.285	0.132	0.847	0.389	0.987	0.994	0.396	0.759
Kazakhstan	0.0676	0.228	0.463	1.06	0.996	0.923	0.398	0.169
Kenya	0.0884	0.0629	0.332	0.8	0.988	0.992	0.792	0.221
Latvia	0.0975	0.516	0.446	1.59	0.996	0.966	0.52	0.00941
Lithuania	0.07	0.0763	0.441	0.98	0.996	0.987	0.521	0.0756
Malaysia	0.185	0.0409	0.582	0.686	0.994	0.996	0.231	0.464

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Mexico	0.0328	0.072	0.227	0.138	0.998	0.999	0.821	0.946
Morocco	0.0225	0.0389	0.293	0.441	0.999	0.992	0.495	0.687
Nepal	0.175	0.287	0.268	1.04	0.998	0.934	0.911	0.171
Netherlands	0.0119	0.0359	0.11	0.154	1	0.998	0.962	0.946
NewZealand	0.0269	0.193	0.25	1.52	0.994	0.956	0.905	0.134
Nigeria	0.048	0.0695	0.335	0.277	0.998	0.997	0.598	0.772
NorthMacedonia	0.11	0.102	0.412	0.638	0.967	0.981	0.72	0.22
Norway	0.123	0.0581	0.425	0.461	0.997	0.995	0.632	0.746
Pakistan	0.312	0.0485	0.444	0.211	0.969	0.996	0.651	0.917
Panama	0.0767	0.0899	0.444	0.34	0.983	0.987	0.353	0.299
Paraguay	0.118	0.407	0.757	1.9	0.982	0.743	0.106	0.0247
Peru	0.52	0.0501	0.622	0.157	0.993	0.998	0.224	0.963
Philippines	0.106	0.0246	0.447	0.22	0.977	0.999	0.255	0.644
Poland	0.0917	0.0944	0.226	0.239	0.997	0.994	0.512	0.673
Portugal	0.0952	0.0261	0.341	0.176	0.99	0.999	0.498	0.875
Qatar	0.399	0.68	0.401	0.933	0.998	0.977	0.897	0.554
Romania	0.0505	0.0531	0.3	0.203	0.997	0.998	0.451	0.754
Russia	0.0885	0.0583	0.0984	0.113	0.998	0.999	0.926	0.96
SaudiArabia	0.0788	0.0981	0.223	0.255	0.991	0.99	0.845	0.868
Senegal	0.0808	0.0641	0.256	0.909	0.999	0.992	0.745	0.273
Serbia	0.0349	0.0315	0.291	0.337	0.999	0.996	0.778	0.575
Singapore	0.21	1.19	0.204	3.06	0.997	0.855	0.9	0.0157
Slovakia	0.0426	0.14	0.59	1.27	0.998	0.967	0.484	0.315
Slovenia	0.0645	0.0389	0.397	0.688	0.997	0.996	0.736	0.53
SouthAfrica	0.172	0.099	0.246	0.201	0.987	0.999	0.914	0.907
SouthKorea	0.149	0.0271	0.359	0.499	0.996	0.995	0.864	0.453
Spain	0.123	0.25	0.435	0.353	0.964	0.995	0.698	0.905
Sweden	0.107	0.0866	0.254	0.242	0.989	0.997	0.542	0.77
Switzerland	0.032	0.2	0.271	0.275	0.998	0.996	0.865	0.914
Thailand	0.2	0.218	0.51	0.85	0.997	0.989	0.757	0.566
Tunisia	0.691	0.0861	0.958	1.04	0.978	0.986	0.528	0.291
Turkey	0.0358	0.0457	0.187	0.116	0.996	0.998	0.859	0.952
UAE	0.0314	0.393	0.12	0.663	0.999	0.924	0.923	0.243
UK	0.0685	0.0286	0.27	0.138	0.99	0.998	0.631	0.937
USA	0.0477	0.0299	0.151	0.0925	0.997	0.999	0.727	0.953

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Figure S7 shows the visualization of fit between data and simulations for all the countries in our sample. These graphs include data and model outputs for reported new cases (blue; left axis in thousands per day) and deaths (red; right axis in thousands per day) starting from the beginning of the epidemic in each country until June 20.



Figure S7- Comparison of data and simulation. New cases in blue (left axis, in thousands per day) and new deaths (red, right axis).

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Estimates for true magnitude of epidemic

Estimates for true cumulative cases (blue; left axis in millions) and deaths (red; right axis in thousands) across different countries up to June 20 are reported in Figure S8.



Figure S8- Estimates and 95% credible intervals for true magnitude of epidemic. Cumulative cases (blue, left axis in millions) and cumulative deaths (red, right axis, in thousands)

Excess deaths

Figure S9 shows the ratio of estimated excess deaths, i.e. COVID-19 fatalities not reported as such, to reported excess deaths, i.e. deaths over historical baseline not accounted for by reported COVID-19 deaths, for the countries for which such data are available.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .



Figure S9- Ratio of estimated excess deaths to reported excess deaths.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Maximum reproduction number

Figure S10 shows the initial reproduction number (R_E) occurring in each country. Reproduction numbers are changing dynamically and transient dynamics may lead to larger than equilibrium numbers if maximum R_E values were used. We therefore use the 90th percentile of simulated reproduction number in this graph. Also note the large credible intervals for these estimates, partly coming from changes in what is included in the 90th percentile (sometimes it includes the highest values and sometimes it does not), as well as the inherent uncertainty when both reproduction number and behavioral and policy responses are estimated: one can have smaller initial R_E and smaller response functions, or larger values for both, and stay consistent with the data.



Figure S10- Maximum reproduction number R_E for each country's outbreak

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Parameter estimates

Figure S11 reports most likely estimates for the vector of country-specific parameters ($\boldsymbol{\theta_i}$). The figure also includes 95% credible intervals for these parameter estimates.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .



medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .



Figure S11- Parameter estimates and 95% credible regions for country-specific parameters.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Future projections

Figure S12 reports country-level projections for new cases and deaths based on the following assumptions (consistent with those reported in Figure 2-D in the main paper). We shift both testing and contact sensitivity to perceived risks to arguably more realistic values between current ones that capture some improvements but not a completely different behavior. Specifically, on July 1st 2020 we shift test rate to a value 20% between the current rates and 0.1% per day (which increases testing in most countries and reduces it in a few). Similarly, sensitivity of contacts to perceived risk is shifted to 20% of the way between estimated country-level values and a high value of 8 that is.



Figure S12- Country level projections until Spring 2021. Daily cases (in thousands, blue, left axis) and daily deaths (red, right axis) are graphed.

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

S5- COMPLETE MODEL DOCUMENTATION

Below we provide complete model equations and units. The model in the .mdl format is available with this appendix as well, and online at https://github.com/tseyanglim/CovidGlobal. Most equations are self-explanatory. The "[…]" notation is used to subscript variables over a set of members. For example, the subscript "Rgn" is used to identify different countries. Therefore [Rgn] indicates that a variable is defined separately for each member of the set "Rgn". Other subscript ranges used in the equations are:

expnt: Used for numerically solving the probability of missing symptoms equation.

pdim: Used for setting policy levels for a few variables.

Priors: Used for implementing the random effects estimation components. Each estimated parameter is mapped into an element of this subscript to simplify vector-based calculations.

Series: The data series (Infection, Death, Recovery).

TstSts: The test status including those confirmed ('Tested') and those unconfirmed ('Notest').

Complete equations and units

1) *a[Rgn] = XIDZ (Potential Test Demand from Susceptible Population[Rgn] , Positive Candidates Interested in Testing Poisson Subset Adj[Rgn] , 1) Units: dmnl*
2) *AbsPrcErr[Rgn,Series] = if then else (DataIncluded[Rgn] = 0, :NA:, ZIDZ (abs (FlowResiduals[Rgn,Series]) , DataFlowOverTime[Rgn,Series])) Units: dmnl*
3) *AbsStd[Priors] = 0.2, 0.3, 0.2, 0.2, 0.0005, 0.2, 30, 0.03, 6, 0.1, 0.1, 0.1, 0.8, 0.1, 1e-05, 10, 0.01, 0.005, 0.03, 10, 10, 10, 0.02*
4) *Active Test Rate[Rgn] = if then else (Time < New Testing Time , DataTestRate[Rgn] , External Test Rate[Rgn]) Units: Person/Day*
5) *ActiveAve[PriorEndoAve] = INITIAL(InputAve[PriorEndoAve] * (1 - SW EndoAve) + SW EndoAve * CalcAve[PriorEndoAve])*
6) *ActiveAve[PMT] = InputAve[PMT]*
7) *Activities Allowed by Government[Rgn] = 1 Units: dmnl*
8) *Additional Asymptomatic Post Detection[Rgn] = Weighted Infected Post Detection Gate[Rgn] * Additional Asymptomatic Relative to Symptomatic[Rgn] / (1 + Additional Asymptomatic Relative to Symptomatic[Rgn]) Units: Person*
9) *Additional Asymptomatic Relative to Symptomatic[Rgn] = ZIDZ (Total Asymptomatic Fraction Net[Rgn] - exp (- Covid Acuity[Rgn]) , 1 - Total Asymptomatic Fraction Net[Rgn]) Units: dmnl*
10) *AdvCntrs[Rgn] = 1 Units: dmnl*
11) *All Recovery[Rgn] = Recovery of Confirmed[Rgn] + Recovery of Untested[Rgn] + sum (Hospital Discharges[Rgn,TstSts!]) Units: Person/Day*
12) *Allocated Fraction COVID Hospitalized[Rgn] = min (1, (- Expected Positive Poisson Covid Patients[Rgn] + Sqrt (Expected Positive Poisson Covid Patients[Rgn] ^ 2 + 4 * Effective Hospital Capacity[Rgn] * Effective Hospital Capacity[Rgn])) / (2 * Effective Hospital Capacity[Rgn])) Units: dmnl*
13) *Allocated Fration NonCOVID Hospitalized[Rgn] = SMOOTHI (Allocated Fraction COVID Hospitalized[Rgn] ^ 2, Hospital Adj T , 1) Units: dmnl*
14) *alp[Rgn,Infection] = min (maxAlp , ialp * alpR[Rgn])*
15) *alp[Rgn,Death] = min (1, dalp * alpR[Rgn])*
16) *alp[Rgn,Test] = min (1, talp * alpR[Rgn]) Units: dmnl*
17) *alpR[Rgn] = 1 Units: dmnl*
18) *Area of Region[Rgn] = GET VDF CONSTANTS(Constant Data File , 'DataConstants[Rgn]', 5) Units: Km*Km*
19) *Average Acuity Hospitalized[Rgn,Tested] = Average Acuity of Positively Tested[Rgn] * XIDZ ((1 - Probability of Missing Acuity Signal at Hospitals[Rgn,Tested] * Fraction Poisson not Hospitalized[Rgn,Tested] ^ 2) , 1 - Fraction Poisson not Hospitalized[Rgn,Tested] , 2 * Probability of Missing Acuity Signal at Hospitals[Rgn,Tested])*
20) *Average Acuity Hospitalized[Rgn,Notest] = ZIDZ (Average Acuity of Untested Poisson Subset[Rgn] * (1 - Probability of Missing Acuity Signal at Hospitals[Rgn,Notest] * Fraction Poisson not Hospitalized[Rgn,Notest] ^ 2) , 1 - Fraction Poisson not Hospitalized[Rgn,Notest]) Units: dmnl*
21) *Average Acuity Not Hospitalized[Rgn,Notest] = ZIDZ (Average Acuity Not Hospitalized Poisson[Rgn,Notest] * Infectious not Tested or in Hospitals Poisson[Rgn] , "Infected Unconfirmed Post-Detection"[Rgn])*

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

22) *Average Acuity Not Hospitalized[Rgn,Tested] = Average Acuity Not Hospitalized Poisson[Rgn,Tested] Units: dmnl*
23) *Average Acuity Not Hospitalized Poisson[Rgn,Tested] = Max (0, Probability of Missing Acuity Signal at Hospitals[Rgn,Tested] * Average Acuity of Positively Tested[Rgn] * Fraction Poisson not Hospitalized[Rgn,Tested])*
24) *Average Acuity Not Hospitalized Poisson[Rgn,Notest] = Max (0, Probability of Missing Acuity Signal at Hospitals[Rgn,Notest] * Average Acuity of Untested Poisson Subset[Rgn] * Fraction Poisson not Hospitalized[Rgn,Notest]) Units: dmnl*
25) *Average Acuity of Positively Tested[Rgn] = Covid Acuity[Rgn] * XIDZ ((1 - Prob Missing Symptom[Rgn] * Fraction Interested not Tested[Rgn] ^ 2) , 1 - Fraction Interested not Tested[Rgn] , 2 * Prob Missing Symptom[Rgn]) Units: dmnl*
26) *Average Acuity of Untested Poisson Subset[Rgn] = ZIDZ (Poisson Subset Reaching Test Gate[Rgn] * Covid Acuity[Rgn] - Positive Tests of Infected[Rgn] * Average Acuity of Positively Tested[Rgn] , Poisson Subset Not Tested Passing Gate[Rgn]) Units: dmnl*
27) *b[Rgn] = ZIDZ (Testing on Living[Rgn] - Positive Candidates Interested in Testing Poisson Subset Adj[Rgn] - Potential Test Demand from Susceptible Population[Rgn] , Positive Candidates Interested in Testing Poisson Subset Adj[Rgn]) Units: dmnl*
28) *Base Fatality Rate for Unit Acuity[Rgn] = 0.0006 Units: dmnl*
29) *Base Fatality Rate for Unit Acuity Net[Rgn] = INITIAL(Base Fatality Rate for Unit Acuity[Rgn] * (1 - SW Gen[BsFtRt]) + SW Gen[BsFtRt] * InputAve[BsFtRt]) Units: dmnl*
30) *BaseError = 5 Units: Person*
31) *Baseline Daily Fraction Susceptible Seeking Tests[Rgn] = 0.001 Units: 1/Day*
32) *Baseline Fatality Multiplier[Rgn] = INITIAL(Demographic Impact on Fatality Relative to China[Rgn] * Base Fatality Rate for Unit Acuity Net[Rgn] * Liver Disease Impact on Fatality[Rgn] * Obesity Impact on Fatality[Rgn] * Chronic Impact on Fatality[Rgn]) Units: dmnl*
33) *Baseline Risk of Transmission by Asymptomatic[Rgn] = INITIAL(Baseline Transmission Multiplier for Untested Symptomatic * Multiplier Transmission Risk for Asymptomatic Net[Rgn]) Units: dmnl*
34) *Baseline Transmission Multiplier for Untested Symptomatic = 1 Units: dmnl*
35) *Bed per Square Kilometer[Rgn] = INITIAL(Nominal Hospital Capacity[Rgn] / Area of Region[Rgn]) Units: Person/(Km*Km)*
36) *Beds per Thousand Population[Rgn] = GET VDF CONSTANTS(Constant Data File , 'DataConstants[Rgn]', 11) Units: dmnl*
37) *CalcAve[Priors] = INITIAL(sum (RegionalInputs[Priors,Rgn!]) / ELMCOUNT(Rgn))*
38) *cft[Rgn,p2] = lnymix[Rgn,p2]*
39) *cft[Rgn,p3] = lnymix[Rgn,p3] - lnymix[Rgn,p2]*
40) *cft[Rgn,p4] = (ln (min (100, Max (1e-06, ZIDZ (lnymix[Rgn,p4] - lnymix[Rgn,p2] , lnymix[Rgn,p3] - lnymix[Rgn,p2]) / ln (2))))) Units: dmnl*
41) *Chng Cml Dth Untst Untrt[Rgn] = Deaths of Symptomatic Untested[Rgn] - Post Mortem Test Rate[Rgn] * Frac Post Mortem from Untreated[Rgn] Units: Person/Day*
42) *Chronic Death Rate[Rgn] = GET VDF CONSTANTS(Constant Data File , 'DataConstants[Rgn]', 17) Units: dmnl*
43) *Chronic Impact on Fatality[Rgn] = INITIAL((Chronic Death Rate[Rgn] / MeanChronic) ^ Sens Chronic Impact Net[Rgn]) Units: dmnl*
44) *Cml Death Frac In Hosp[Rgn] = XIDZ (Cumulative Deaths at Hospital[Rgn,Tested] + Cumulative Deaths at Hospital[Rgn,Notest] , Cumulative Deaths[Rgn] , 1) Units: dmnl*
45) *Cml Death fraction in hospitals large enough = sum (if then else (Cml Death Frac In Hosp[Rgn!] < MinHspDTresh , 1, 0)) Units: dmnl*
46) *Cml Death Hsp Inc[Rgn,Tested] = Hospitalized Infectious Deaths[Rgn,Tested] + PostMortemCorrection[Rgn]*
47) *Cml Death Hsp Inc[Rgn,Notest] = Hospitalized Infectious Deaths[Rgn,Notest] - PostMortemCorrection[Rgn] Units: Person/Day*
48) *Cml Known Death Frac Hosp[Rgn] = XIDZ (Cumulative Deaths at Hospital[Rgn,Tested] , Cumulative Deaths[Rgn] , 1) Units: dmnl*
49) *CmltErrPW = 2 Units: dmnl*
50) *CmltPenaltyScl = 0 Units: dmnl*
51) *CmltToInclude[Series] = 0, 0, 0 Units: dmnl*
52) *Confirmation Impact on Contact[Rgn] = 0.002 Units: dmnl*
53) *Confirmed Recovered[Rgn] = INTEG(Recovery of Confirmed[Rgn] , 0) Units: Person*
54) *Constant Data File :IS: 'CovidModelInputs - ConstantData.vdf'*
55) *Contacts Relative to Normal[Rgn] = min (Voluntary Reduction in Contacts[Rgn] , Activities Allowed by Government[Rgn]) Units: dmnl*

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

56) *Continue without Testing[Rgn] = Reaching Testing Gate[Rgn] - Symptomatic Infected to Testing[Rgn] - Untested symptomatic Infected to Hospital[Rgn]* Units: Person/Day
57) *Count Missed Death[Rgn] = if then else (Excess Death Start Count[Rgn] = :NA:, 0, if then else (Time >= Excess Death Start Count[Rgn] :AND: Time <= Excess Death End Count[Rgn] , Cml Death Hsp Inc[Rgn,Notest] + Chng Cml Dth Untst Untrt[Rgn] , 0))* Units: Person/Day
58) *Covid Acuity[Rgn] = Flu Acuity * Covid Acuity Relative to Flu Net[Rgn]* Units: dmnl
59) *Covid Acuity Relative to Flu[Rgn] = 6* Units: dmnl
60) *Covid Acuity Relative to Flu Net[Rgn] = INITIAL(Covid Acuity Relative to Flu[Rgn] * (1 - SW Gen[Acty]) + SW Gen[Acty] * InputAve[Acty])* Units: dmnl
61) *Covid Poisson Fraction in Hospital[Rgn] = ZIDZ (Total Covid Hospitalized[Rgn] , Infectious not Tested or in Hospitals Poisson[Rgn] + Infectious Confirmed Not Hospitalized[Rgn] + Total Covid Hospitalized[Rgn])* Units: dmnl
62) *CRW[Rgn]* Units: dmnl
63) *Cumulative Cases[Rgn] = INTEG(New Cases[Rgn] , 0)* Units: Person
64) *Cumulative Confirmed Cases[Rgn] = Infectious Confirmed Not Hospitalized[Rgn] + Hospitalized Infectious[Rgn,Tested] + Cumulative Deaths of Confirmed[Rgn] + Cumulative Confirmed Recovered[Rgn]* Units: Person
65) *Cumulative Confirmed Recovered[Rgn] = Confirmed Recovered[Rgn] + Cumulative Recovered at Hospitals[Rgn,Tested]* Units: Person
66) *Cumulative Death Fraction[Rgn] = ZIDZ (Cumulative Deaths[Rgn] , Cumulative Deaths[Rgn] + Cumulative Recoveries[Rgn])* Units: dmnl
67) *Cumulative Deaths[Rgn] = INTEG(Death Rate[Rgn] , 0)* Units: Person
68) *Cumulative Deaths at Hospital[Rgn,TstSts] = INTEG(Cml Death Hsp Inc[Rgn,TstSts] , 0)* Units: Person
69) *Cumulative Deaths of Confirmed[Rgn] = Cumulative Deaths at Hospital[Rgn,Tested] + Cumulative Deaths of Confirmed Untreated[Rgn]* Units: Person
70) *Cumulative Deaths of Confirmed Untreated[Rgn] = INTEG(Deaths of Confirmed[Rgn] + Post Mortem Test Untreated[Rgn] , 0)* Units: Person
71) *Cumulative Deaths Untested Untreated[Rgn] = INTEG(Chng Cml Dth Untst Untrt[Rgn] , 0)* Units: Person
72) *Cumulative Fraction Total Cases Hospitalized[Rgn] = ZIDZ (sum (Cumulative Deaths at Hospital[Rgn,TstSts!] + Cumulative Recovered at Hospitals[Rgn,TstSts!] + Hospitalized Infectious[Rgn,TstSts!]) , Cumulative Cases[Rgn])* Units: dmnl
73) *Cumulative Missed Death[Rgn] = INTEG(Count Missed Death[Rgn] , 0)* Units: Person
74) *Cumulative Negative Tests[Rgn] = INTEG(Negative Test Results[Rgn] , 0)* Units: Person
75) *Cumulative Recovered at Hospitals[Rgn,TstSts] = INTEG(Hospital Discharges[Rgn,TstSts] , 0)* Units: Person
76) *Cumulative Recoveries[Rgn] = INTEG(All Recovery[Rgn] , 0)* Units: Person
77) *Cumulative Tests Conducted[Rgn] = INTEG(SimTestRate[Rgn] , 0)* Units: Person
78) *Cumulative Tests Data[Rgn] = INTEG(TstInc[Rgn] , 0)* Units: Person
79) *Current Test Rate per Capita[Rgn] = INITIAL(if then else (DataLastTestRate[Rgn] = :NA:, 0, DataLastTestRate[Rgn] / Population[Rgn]))* Units: 1/Day
80) *dalp = 0.1* Units: dmnl
81) *Data Excess Deaths[Rgn] = GET VDF CONSTANTS(Constant Data File , 'DataConstants[Rgn]', 15)* Units: Person
82) *Data Pseudo Case Fatality[Rgn] = ZIDZ (DataCmltDeath[Rgn] , DataCmltInfection[Rgn])* Units: dmnl
83) *DataAttentionTime[Rgn] = GET VDF CONSTANTS(Constant Data File , 'DataConstants[Rgn]', 9)* Units: Day
84) *DataCmltDeath[Rgn]* Units: Person
85) *DataCmltInfection[Rgn]* Units: Person
86) *DataCmltOverTime[Rgn,Infection] :RAW: := DataCmltInfection[Rgn]*
87) *DataCmltOverTime[Rgn,Death] :RAW: := DataCmltDeath[Rgn]*
88) *DataCmltOverTime[Rgn,Test] = DataCmltTest[Rgn]* Units: Person
89) *DataCmltTest[Rgn]* Units: Person
90) *DataFlowDeath[Rgn] :RAW:* Units: Person/Day
91) *DataFlowInfection[Rgn]* Units: Person/Day
92) *DataFlowOverTime[Rgn,Infection] :RAW: := DataFlowInfection[Rgn]*
93) *DataFlowOverTime[Rgn,Death] :RAW: := DataFlowDeath[Rgn]*
94) *DataFlowOverTime[Rgn,Test] :RAW: := DataTestRate[Rgn]* Units: Person/Day
95) *DataFlowRecovery[Rgn] :RAW:* Units: Person/Day
96) *DataIncluded[Rgn] = if then else (Max (Cumulative Deaths[Rgn] , Max (Cumulative Confirmed Cases[Rgn] , DataCmltInfection[Rgn])) > ThrsInc[Rgn] , 1, 0) * DataLimitFromTime* Units: dmnl
97) *DataLastTestRate[Rgn] = INITIAL(GET DATA AT TIME (DataTestRate[Rgn] , min (LastTestDate[Rgn] , New Testing Time)))* Units: Person/Day

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

98) *DataLimitFromTime = if then else (Time > Max Time Data Used , 0, 1)* Units: dmnl
99) *DataTestCapacity[Rgn]* Units: Person/Day
100) *DataTestRate[Rgn]* Units: Person/Day
101) *Day of First Case Report in JHU Database = 99* Units: Day
102) *Days per Year = 365* Units: Day/Year
103) *Death Rate[Rgn] = Deaths of Confirmed[Rgn] + Deaths of Symptomatic Untested[Rgn] + sum (Hospitalized Infectious Deaths[Rgn,TstSts!])* Units: Person/Day
104) *Deaths of Confirmed[Rgn] = Tested Untreated Resolution[Rgn] * Fatality Rate Untreated[Rgn,Tested]* Units: Person/Day
105) *Deaths of Symptomatic Untested[Rgn] = Infectious not Tested or in Hospitals Poisson[Rgn] / "Post-Detection Phase Resolution Time" * Fatality Rate Untreated[Rgn,Notest]* Units: Person/Day
106) *Delay Order = 1* Units: dmnl
107) *Demographic Impact on Fatality Relative to China[Rgn] = GET VDF CONSTANTS(Constant Data File , 'DataConstants[Rgn]', 12)* Units: dmnl
108) *Di[Rgn,Series] = DataFlowOverTime[Rgn,Series]* Units: Person/Day
109) *Discount Rate Annual = 0.03* Units: 1/Year
110) *Discount Rate per Day = INITIAL(Discount Rate Annual / Days per Year)* Units: 1/Day
111) *Dread Factor in Risk Perception[Rgn] = 25* Units: dmnl
112) *Dread Factor in Risk Perception Net[Rgn] = if then else (Response Policy Time On < Time , Dread Factor Policy * Response Policy Weight[dfcP] + (1 - Response Policy Weight[dfcP]) * Dread Factor in Risk Perception[Rgn] , Dread Factor in Risk Perception[Rgn])* Units: dmnl
113) *Dread Factor Policy = 3000* Units: dmnl
114) *Effective Hospital Capacity[Rgn] = Nominal Hospital Capacity[Rgn] * Normalized Hospital density[Rgn] ^ Impact of Population Density on Hospital Availability[Rgn]* Units: Person
115) *eps = 0.001* Units: Person/Day
116) *Excess Death End Count[Rgn] = GET VDF CONSTANTS(Constant Data File , 'DataConstants[Rgn]', 14)* Units: Day
117) *Excess Death Mean Frac = 0.9* Units: dmnl
118) *Excess Death Range Frac = 0.2* Units: dmnl
119) *Excess Death Rate Error[Rgn] = if then else (Data Excess Deaths[Rgn] < 50, 0, ZIDZ (Cumulative Missed Death[Rgn] - Excess Death Mean Frac * Data Excess Deaths[Rgn] , Excess Death Range Frac * Data Excess Deaths[Rgn]) ^ 4)* Units: dmnl
120) *Excess Death Start Count[Rgn] = GET VDF CONSTANTS(Constant Data File , 'DataConstants[Rgn]', 13)* Units: Day
121) *Expected Positive Poisson Covid Patients[Rgn] = sum (Potential Hospital Demand[Rgn,TstSts!]) * "Post-Detection Phase Resolution Time"* Units: Person
122) *expnt : (p2-p4)*
123) *External Test Rate[Rgn] = Population[Rgn] * Policy Test Rate[Rgn]* Units: Person/Day
124) *Extrapolated Estimator[Rgn] = if then else (Covid Acuity Relative to Flu Net[Rgn] > 1, cft[Rgn,p2] + cft[Rgn,p3] * (Covid Acuity Relative to Flu Net[Rgn] - 1) ^ cft[Rgn,p4] , lnymix[Rgn,p2])* Units: dmnl
125) *F[Rgn] = Utility from Normal Activities[Rgn] / (Utility from Limited Activities[Rgn] + Utility from Normal Activities[Rgn])* Units: dmnl
126) *F0[Rgn] = INITIAL(F[Rgn])* Units: dmnl
127) *Fatality Rate Treated[Rgn,TstSts] = min (1, Baseline Fatality Multiplier[Rgn] * Impact of Treatment on Fatality Rate[Rgn] * Average Acuity Hospitalized[Rgn,TstSts] ^ Sensitivity of Fatality Rate to Acuity Net[Rgn])* Units: dmnl
128) *Fatality Rate Untreated[Rgn,TstSts] = min (1, Baseline Fatality Multiplier[Rgn] * Average Acuity Not Hospitalized Poisson[Rgn,TstSts] ^ Sensitivity of Fatality Rate to Acuity Net[Rgn])* Units: dmnl
129) *Final Test Rate Per Capita[Rgn] = INITIAL(Current Test Rate per Capita[Rgn] + Weight Max in Test Goal * (Max Test Rate per Capita - Current Test Rate per Capita[Rgn]))* Units: 1/Day
130) *FINAL TIME = 250* Units: Day
131) *FlowResiduals[Rgn,Series] = if then else (DataFlowOverTime[Rgn,Series] = :NA:, :NA:, DataFlowOverTime[Rgn,Series] - SimFlowOverTime[Rgn,Series])* Units: Person/Day
132) *FlowToInclude[Series] = 1, 1, 0* Units: dmnl
133) *Flu Acuity = 1* Units: dmnl
134) *Flu Acuity Relative to Covid[Rgn] = Flu Acuity / Covid Acuity[Rgn]* Units: dmnl
135) *Frac Post Mortem from Untreated[Rgn] = SMOOTHI (ZIDZ (Deaths of Symptomatic Untested[Rgn] , Deaths of Symptomatic Untested[Rgn] + Hospitalized Infectious Deaths[Rgn,Notest]) , Post Mortem Test Delay , 1)* Units: dmnl
136) *FracThresh = 0.001* Units: dmnl

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

137) *Fraction Covid Death In Hospitals Previously Tested[Rgn] = ZIDZ (Hospitalized Infectious Deaths[Rgn,Tested] , sum (Hospitalized Infectious Deaths[Rgn,TstSts!])) Units: dmnl*
138) *Fraction Covid Hospitalized Positively Tested[Rgn] = ZIDZ (Hospitalized Infectious[Rgn,Tested] , Total Covid Hospitalized[Rgn]) Units: dmnl*
139) *Fraction Interested not Tested[Rgn] = 1 - ZIDZ (Total Test on Covid Patients[Rgn] , Positive Candidates Interested in Testing Poisson Subset[Rgn]) Units: dmnl*
140) *Fraction Interseted not Correctly Tested[Rgn] = 1 - (1 - Fraction Interested not Tested[Rgn]) * Sensitivity of COVID Test Units: dmnl*
141) *Fraction of Additional Symptomatic[Rgn] = Additional Asymptomatic Relative to Symptomatic[Rgn] / (1 + Additional Asymptomatic Relative to Symptomatic[Rgn]) Units: dmnl*
142) *Fraction of Fatalities Screened Post Mortem[Rgn] = Indicated Fraction Post Mortem Testing[Rgn] * Switch for Government Response[Rgn] Units: dmnl*
143) *Fraction of Population Hospitalized for Covid[Rgn] = Total Covid Hospitalized[Rgn] / Population[Rgn] Units: dmnl*
144) *Fraction Poisson not Hospitalized[Rgn,Tested] = exp (- Average Acuity of Positively Tested[Rgn] * (1 - Probability of Missing Acuity Signal at Hospitals[Rgn,Tested]))*
145) *Fraction Poisson not Hospitalized[Rgn,Notest] = exp (- Average Acuity of Untested Poisson Subset[Rgn] * (1 - Probability of Missing Acuity Signal at Hospitals[Rgn,Notest])) Units: dmnl*
146) *Fraction Seeking Test[Rgn] = 1 Units: dmnl*
147) *Fraction Tests Positive[Rgn] = ZIDZ (Positive Tests of Infected[Rgn] , Testing on Living[Rgn]) Units: dmnl*
148) *Fraction Tests Positive Data[Rgn] = min (1, ZIDZ (DataFlowInfection[Rgn] , Active Test Rate[Rgn])) Units: dmnl*
149) *Fractional Value of Limited Activities = 0.5 Units: dmnl*
150) *Global Cases = sum (Cumulative Cases[Rgn!]) Units: Person*
151) *Global Deaths = sum (Cumulative Deaths[Rgn!]) Units: Person*
152) *Global IFR = ZIDZ (Global Deaths , Global Cases) Units: dmnl*
153) *Government Response Start Time[Rgn] = INITIAL(DataAttentionTime[Rgn] + Day of First Case Report in JHU Database) Units: Day*
154) *Hazard of Symptomatic Infection[Rgn] = Infection Rate[Rgn] / Susceptible[Rgn] * (1 - Total Asymptomatic Fraction Net[Rgn]) Units: 1/Day*
155) *Herd Immunity Fraction = 0.8 Units: dmnl*
156) *Hospital Adj T = 1 Units: Day*
157) *Hospital Admission Infectious[Rgn,TstSts] = Hospital Admits All[Rgn,TstSts] Units: Person/Day*
158) *Hospital Admit Ratio[Rgn,TstSts] = XIDZ (Hospital Admits All[Rgn,TstSts] , Potential Hospital Demand[Rgn,TstSts] , 1) Units: dmnl*
159) *Hospital Admits All[Rgn,Tested] = Hospital Demand from Tested[Rgn] * Allocated Fraction COVID Hospitalized[Rgn]*
160) *Hospital Admits All[Rgn,Notest] = Hospital Demand from Not Tested[Rgn] * Allocated Fraction COVID Hospitalized[Rgn] Units: Person/Day*
161) *Hospital Demand from Not Tested[Rgn] = Poisson Subset Not Tested Passing Gate[Rgn] * (1 - exp (- Average Acuity of Untested Poisson Subset[Rgn] * (1 - PMAS Unconfirmed for Hospital Demand[Rgn]))) Units: Person/Day*
162) *Hospital Demand from Tested[Rgn] = Positive Tests of Infected[Rgn] * (1 - exp (- Average Acuity of Positively Tested[Rgn] * (1 - PMAS Confirmed for Hospital Demand[Rgn]))) Units: Person/Day*
163) *Hospital Discharges[Rgn,TstSts] = (1 - Fatality Rate Treated[Rgn,TstSts]) * Hospital Outflow Covid Positive[Rgn,TstSts] Units: Person/Day*
164) *Hospital Outflow Covid Positive[Rgn,TstSts] = Hospitalized Infectious[Rgn,TstSts] / Hospitalized Resolution Time Units: Person/Day*
165) *Hospitalized CFR Cumulative[Rgn,TstSts] = ZIDZ (Cumulative Deaths at Hospital[Rgn,TstSts] , Cumulative Deaths at Hospital[Rgn,TstSts] + Cumulative Recovered at Hospitals[Rgn,TstSts]) Units: dmnl*
166) *Hospitalized Infectious[Rgn,TstSts] = INTEG(Hospital Admission Infectious[Rgn,TstSts] - Hospitalized Infectious Deaths[Rgn,TstSts] - Hospital Discharges[Rgn,TstSts] , 0) Units: Person*
167) *Hospitalized Infectious Deaths[Rgn,TstSts] = Fatality Rate Treated[Rgn,TstSts] * Hospital Outflow Covid Positive[Rgn,TstSts] Units: Person/Day*
168) *Hospitalized Resolution Time = 20 Units: Day*
169) *Hospitalized True CFR[Rgn] = ZIDZ (sum (Hospitalized Infectious Deaths[Rgn,TstSts!]) , sum (Hospital Outflow Covid Positive[Rgn,TstSts!])) Units: dmnl*
170) *Hospitalized True CFR Cumulative[Rgn] = ZIDZ (sum (Cumulative Deaths at Hospital[Rgn,TstSts!]) , sum (Cumulative Deaths at Hospital[Rgn,TstSts!] + Cumulative Recovered at Hospitals[Rgn,TstSts!])) Units: dmnl*
171) *ialp = 0.1 Units: dmnl*
172) *Impact of Population Density on Hospital Availability[Rgn] = 0.72 Units: dmnl*

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

173) *Impact of Treatment on Fatality Rate[Rgn] = 0.32 Units: dmnl*
174) *Incubation Period = 5.6 Units: Day*
175) *Indicated fraction negative demand tested[Rgn] = 1 - exp (Flu Acuity * (Prob Missing Symptom[Rgn] - 1)) Units: dmnl*
176) *Indicated fraction positive demand tested[Rgn] = 1 - exp (Covid Acuity[Rgn] * (Prob Missing Symptom[Rgn] - 1)) Units: dmnl*
177) *Indicated Fraction Post Mortem Testing[Rgn] = Fraction Covid Death In Hospitals Previously Tested[Rgn] ^ Sensitivity Post Mortem Testing to Capacity[Rgn] Units: dmnl*
178) *Indicated Risk of Life Loss[Rgn] = min (1, Switch for Government Response[Rgn] * Perceived Hazard of Infection[Rgn] * Dread Factor in Risk Perception Net[Rgn] * PseudoCFR / Discount Rate per Day) Units: dmnl*
179) *Infected pre Detection[Rgn] = INTEG(Onset of Symptoms[Rgn] - Continue without Testing[Rgn] - Symptomatic Infected to Testing[Rgn] - Untested symptomatic Infected to Hospital[Rgn] , 0) Units: Person*
180) *"Infected Unconfirmed Post-Detection"[Rgn] = INTEG(Continue without Testing[Rgn] - Deaths of Symptomatic Untested[Rgn] - Recovery of Untested[Rgn] , 0) Units: Person*
181) *Infection Rate[Rgn] = Infectious Contacts[Rgn] * (Susceptible[Rgn] / Population[Rgn]) * Weather Effect on Transmission[Rgn] Units: Person/Day*
182) *Infectious Confirmed Not Hospitalized[Rgn] = INTEG(Positive Testing of Infected Untreated[Rgn] - Deaths of Confirmed[Rgn] - Recovery of Confirmed[Rgn] , 0) Units: Person*
183) *Infectious Contacts[Rgn] = ("Pre-Symptomatic Infected"[Rgn] * Transmission Multiplier Presymptomatic[Rgn] + Infected pre Detection[Rgn] * Transmission Multiplier Pre Detection[Rgn] + (Additional Asymptomatic Post Detection[Rgn] + "Poisson Not-tested Asymptomatic"[Rgn]) * Baseline Risk of Transmission by Asymptomatic[Rgn] + (Infectious not Tested or in Hospitals Poisson[Rgn] - "Poisson Not-tested Asymptomatic"[Rgn]) * Baseline Transmission Multiplier for Untested Symptomatic + Infectious Confirmed Not Hospitalized[*
184) *Rgn] * Transmission Multiplier for Confirmed[Rgn] + sum (Hospitalized Infectious[Rgn,TstSts!] * Transmission Multiplier for Hospitalized[Rgn,TstSts!])) * Reference Force of Infection[Rgn] * Contacts Relative to Normal[Rgn] Units: Person/Day*
185) *Infectious not Tested or in Hospitals Poisson[Rgn] = "Infected Unconfirmed Post-Detection"[Rgn] - Additional Asymptomatic Post Detection[Rgn] Units: Person*
186) *Initial Population[Rgn] = GET VDF CONSTANTS(Constant Data File , 'DataConstants[Rgn]', 1) Units: Person*
187) *INITIAL TIME = 30 Units: Day*
188) *InpAveErr = INITIAL(sum (InpAveErrCmp[PriorEndoAve!]))*
189) *InpAveErrCmp[PriorEndoAve] = INITIAL((abs (CalcAve[PriorEndoAve] - InputAve[PriorEndoAve]) / Max (1e-06, CalcAve[PriorEndoAve]) * SW EndoAve))*
190) *InputAve[Priors] = 1, 1.8, 0.47, 1, 0.0009, 0.81, 58, 0.017, 6.2, 0.1, 0.24, 0.4, 2.27, 0.52, 0.00055, 0.76, 5.9, 2.07, 0.55, 1e-06, 1e-06, 1e-06, 0.28*
191) *IrD : Travel,InformalDeath*
192) *Known death fraction in hospitals large enough = sum (if then else (Cml Known Death Frac Hosp[Rgn!] < MinHspDTreshAdv , 1, 0) * AdvCntrs[Rgn!]) Units: dmnl*
193) *LastTestDate[Rgn] = INITIAL(GET DATA Last TIME (DataTestRate[Rgn])) Units: Day*
194) *Liver Disease Impact on Fatality[Rgn] = INITIAL((Liver Disease Rate[Rgn] / MeanLiver) ^ Sens Liver Impact Net[Rgn]) Units: dmnl*
195) *Liver Disease Rate[Rgn] = GET VDF CONSTANTS(Constant Data File , 'DataConstants[Rgn]', 18) Units: dmnl*
196) *lnymix[Rgn,expnt] = - ln (Max (1e-06, 1 - Ymix[Rgn,expnt])) Units: dmnl*
197) *lnymix 0[Rgn,expnt] = - ln (Max (1e-06, 1 - Ymix[Rgn,expnt])) Units: dmnl*
198) *Max Test Rate per Capita = 0.001 Units: 1/Day*
199) *Max Time Data Used = 247 Units: Day*
200) *maxAlp = 1 Units: dmnl*
201) *MaxData[Rgn] = INITIAL(GET DATA MAX (DataCmltInfection[Rgn] , 0, 500)) Units: Person*
202) *MaxRTresh = 8 Units: dmnl*
203) *MeanChronic = GET VDF CONSTANTS(Constant Data File , 'MeanChronic', 1) Units: dmnl*
204) *MeanLiver = GET VDF CONSTANTS(Constant Data File , 'MeanLiver', 1) Units: dmnl*
205) *MeanObesity = GET VDF CONSTANTS(Constant Data File , 'MeanObesity', 1) Units: dmnl*
206) *Min Contact Fraction[Rgn] = 0.04 Units: dmnl*
207) *Min Excess Death Attributable to COVID = 0.5 Units: dmnl*
208) *MinAdjT = 1 Units: Day*
209) *MinHspDTresh = 0.2 Units: dmnl*
210) *MinHspDTreshAdv = 0.8 Units: dmnl*

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

211) MinSuscTresh = 0.7 Units: dmnl
212) Mu[Rgn,Series] = Max (eps , SimFlowOverTime[Rgn,Series]) Units: Person/Day
213) Multiplier Recent Infections to Test[Rgn] = 45 Units: dmnl
214) Multiplier Transmission Risk for Asymptomatic[Rgn] = 0.3 Units: dmnl
215) Multiplier Transmission Risk for Asymptomatic Net[Rgn] = INITIAL(Multiplier Transmission Risk for Asymptomatic[Rgn] * (1 - SW Gen[MTrAsym]) + SW Gen[MTrAsym] * InputAve[MTrAsym]) Units: dmnl
216) NBL1[Rgn,Series] = if then else (DataFlowOverTime[Rgn,Series] = 0, - ln (1 + alp[Rgn,Series] * Mu[Rgn,Series]) / alp[Rgn,Series] , 0) Units: dmnl
217) NBL2[Rgn,Series] = if then else (DataFlowOverTime[Rgn,Series] > 0, GAMMA LN (Di[Rgn,Series] + 1 / alp[Rgn,Series]) - GAMMA LN (1 / alp[Rgn,Series]) - GAMMA LN (Di[Rgn,Series] + 1) - (Di[Rgn,Series] + 1 / alp[Rgn,Series]) * ln (1 + alp[Rgn,Series] * Mu[Rgn,Series]) + Di[Rgn,Series] * (ln (alp[Rgn,Series]) + ln (Mu[Rgn,Series])) , 0) Units: dmnl
218) NBL3[Rgn,Series] = if then else (Di[Rgn,Series] > 0, - GAMMA LN (Di[Rgn,Series] + 1) - (Di[Rgn,Series] + 1 / alp[Rgn,Series]) * ln (1 + alp[Rgn,Series] * Mu[Rgn,Series]) + Di[Rgn,Series] * (ln (alp[Rgn,Series]) + ln (Mu[Rgn,Series])) , 0) Units: dmnl
219) NBLLFlow[Rgn,Series] = (NBL1[Rgn,Series] + NBL2[Rgn,Series]) * FlowToInclude[Series] * DataIncluded[Rgn] Units: dmnl
220) Negative Test Results[Rgn] = Testing on Living[Rgn] - Positive Tests of Infected[Rgn] Units: Person/Day
221) New Cases[Rgn] = Infection Rate[Rgn] Units: Person/Day
222) New Testing Time = 250 Units: Day
223) Nominal Hospital Capacity[Rgn] = INITIAL(Initial Population[Rgn] * Beds per Thousand Population[Rgn] / 1000) Units: Person
224) Normalized Hospital density[Rgn] = INITIAL(Bed per Square Kilometer[Rgn] / Reference Hospital Density) Units: dmnl
225) Not too few susceptibles = sum (if then else (SuscFrac[Rgn!] < MinSuscTresh , 1, 0)) Units: dmnl
226) Obesity Impact on Fatality[Rgn] = INITIAL((Obesity Rates[Rgn] / MeanObesity) ^ Sens Obesity Impact Net[Rgn]) Units: dmnl
227) Obesity Rates[Rgn] = GET VDF CONSTANTS(Constant Data File , 'DataConstants[Rgn]', 16) Units: dmnl
228) Onset of Symptoms[Rgn] = DELAY N (Infection Rate[Rgn] , Incubation Period ,0, Delay Order) Units: Person/Day
229) Onset to Detection Delay = 5 Units: Day
230) Overall Death Fraction[Rgn] = ZIDZ (Death Rate[Rgn] , All Recovery[Rgn]) Units: dmnl
231) Patient Zero Arrival[Rgn] = if then else (Time < Patient Zero Arrival Time[Rgn] :AND: Time + TIME STEP >= Patient Zero Arrival Time[Rgn] , PatientZero / TIME STEP , 0) Units: Person/Day
232) Patient Zero Arrival Time[Rgn] = 1 Units: Day
233) PatientZero = 1 Units: Person
234) payoff = 0 Units: dmnl
235) pdim : tstP,dfcP,dgtP,scuP
236) Perceived Hazard of Infection[Rgn] = (Weight on Reported Probability of Infection[Rgn] * Reported Hazard of Infection[Rgn] + (1 - Weight on Reported Probability of Infection[Rgn]) * Hazard of Symptomatic Infection[Rgn]) Units: 1/Day
237) Perceived Risk of Life Loss[Rgn] = INTEG((Indicated Risk of Life Loss[Rgn] - Perceived Risk of Life Loss[Rgn]) / if then else (Indicated Risk of Life Loss[Rgn] > Perceived Risk of Life Loss[Rgn] , Time to Upgrade Risk[Rgn] , Time to Downgrade Risk Net[Rgn]) , 0) Units: dmnl
238) PG1 : PG
239) PMAS Confirmed for Hospital Demand[Rgn] = (1 - Reference COVID Hospitalization Fraction Confirmed[Rgn]) ^ (1 / Average Acuity of Positively Tested[Rgn]) Units: dmnl
240) PMAS Unconfirmed for Hospital Demand[Rgn] = PMAS Confirmed for Hospital Demand[Rgn] + (1 - PMAS Confirmed for Hospital Demand[Rgn]) * Untested PMAS Gap with Tested[Rgn] Units: dmnl
241) "Poisson Not-tested Asymptomatic"[Rgn] = Infectious not Tested or in Hospitals Poisson[Rgn] * exp (- Average Acuity Not Hospitalized Poisson[Rgn,Notest]) Units: Person
242) Poisson Subset Not Tested Passing Gate[Rgn] = Poisson Subset Reaching Test Gate[Rgn] - Positive Tests of Infected[Rgn] Units: Person/Day
243) Poisson Subset Reaching Test Gate[Rgn] = Reaching Testing Gate[Rgn] / (1 + Additional Asymptomatic Relative to Symptomatic[Rgn]) Units: Person/Day
244) Policy Test Rate[Rgn] = if then else (Time < New Testing Time , Current Test Rate per Capita[Rgn] , Final Test Rate Per Capita[Rgn]) Units: 1/Day
245) Population[Rgn] = Infected pre Detection[Rgn] + "Infected Unconfirmed Post-Detection"[Rgn] + Susceptible[Rgn] + Recovered Unconfirmed[Rgn] + Confirmed Recovered[Rgn] + Infectious Confirmed Not Hospitalized[Rgn] + "Pre-

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

Symptomatic Infected"[Rgn] + sum (Hospitalized Infectious[Rgn,TstSts!]) + sum (Cumulative Recovered at Hospitals[Rgn,TstSts!]) Units: Person

*246) Positive Candidates Interested in Testing Poisson Subset[Rgn] = Poisson Subset Reaching Test Gate[Rgn] * Fraction Seeking Test[Rgn] Units: Person/Day*

*247) Positive Candidates Interested in Testing Poisson Subset Adj[Rgn] = Max (0.001 * Potential Test Demand from Susceptible Population[Rgn] , Positive Candidates Interested in Testing Poisson Subset[Rgn]) Units: Person/Day*

*248) Positive Testing of Infected Untreated[Rgn] = Positive Tests of Infected[Rgn] * Fraction Poisson not Hospitalized[Rgn,Tested] Units: Person/Day*

*249) Positive Tests of Infected[Rgn] = Positive Candidates Interested in Testing Poisson Subset[Rgn] * (1 - Fraction Interseted not Correctly Tested[Rgn]) Units: Person/Day*

250) Post Mortem Test Delay = 1 Units: Day

*251) Post Mortem Test Rate[Rgn] = Post Mortem Tests Total[Rgn] * Sensitivity of COVID Test Units: Person/Day*

*252) Post Mortem Test Untreated[Rgn] = Post Mortem Test Rate[Rgn] * Frac Post Mortem from Untreated[Rgn] Units: Person/Day*

*253) Post Mortem Testing Need[Rgn] = SMOOTHI ((Deaths of Symptomatic Untested[Rgn] + Hospitalized Infectious Deaths[Rgn,Notest]) * Fraction of Fatalities Screened Post Mortem[Rgn] , Post Mortem Test Delay , 0) Units: Person/Day*

254) Post Mortem Tests Total[Rgn] = min (Post Mortem Testing Need[Rgn] , Active Test Rate[Rgn]) Units: Person/Day

255) "Post-Detection Phase Resolution Time" = 10 Units: Day

*256) PostMortemCorrection[Rgn] = min (Hospitalized Infectious[Rgn,Notest] / MinAdjT , Post Mortem Test Rate[Rgn] * (1 - Frac Post Mortem from Untreated[Rgn])) Units: Person/Day*

257) Potential Hospital Demand[Rgn,Notest] = Hospital Demand from Not Tested[Rgn]

258) Potential Hospital Demand[Rgn,Tested] = Hospital Demand from Tested[Rgn] Units: Person/Day

*259) Potential Test Demand from Susceptible Population[Rgn] = (Susceptible[Rgn] + Recovered Unconfirmed[Rgn] + Cumulative Recovered at Hospitals[Rgn,Notest]) * (Baseline Daily Fraction Susceptible Seeking Tests[Rgn] * Fraction Seeking Test[Rgn] + Multiplier Recent Infections to Test[Rgn] / Population[Rgn] * Recent Detected Infections[Rgn]) Units: Person/Day*

260) "Pre-Symptomatic Infected"[Rgn] = INTEG(Infection Rate[Rgn] + Patient Zero Arrival[Rgn] - Onset of Symptoms[Rgn] , 0) Units: Person

261) PriorEndoAve : UpAdj,DwnAdj,RFI,RfSkTs,WRpPIn,MInfTs,MnCnFrc,SnCnRdUt,CfImCn,ImPDnHs,ImTrFt,DrdFac,MxHsFr,BsFtRt,SnsWth,Acty,SnFtAc,TtAsyFr,ObsImp,ChrImp,LivImp,MTrAsym

262) PriorErrs[Rgn,Priors] = INITIAL(ZIDZ (ActiveAve[Priors] - RegionalInputs[Priors,Rgn] , AbsStd[Priors]) ^ 2 / 2)

263) PriorGen : BsFtRt,SnsWth,Acty,SnFtAc,TtAsyFr,ObsImp,ChrImp,LivImp,MTrAsym

264) Priors : UpAdj,DwnAdj,RFI,PMT,RfSkTs,WRpPIn,MInfTs,MnCnFrc,SnCnRdUt,CfImCn,ImPDnHs,ImTrFt,DrdFac,MxHsFr,BsFtRt,SnsWth,Acty,SnFtAc,TtAsyFr,ObsImp,ChrImp,LivImp,MTrAsym

265) Prob Missing Symptom[Rgn] = Max (0, ln (Y[Rgn]) / Flu Acuity + 1) Units: dmnl

266) Probability of Missing Acuity Signal at Hospitals[Rgn,Tested] = ZIDZ (ln (Max (1e-06, 1 - ZIDZ (Hospital Admits All[Rgn,Tested] , Positive Tests of Infected[Rgn]))) , Average Acuity of Positively Tested[Rgn]) + 1

267) Probability of Missing Acuity Signal at Hospitals[Rgn,Notest] = ZIDZ (ln (Max (1e-06, 1 - ZIDZ (Hospital Admits All[Rgn,Notest] , Poisson Subset Not Tested Passing Gate[Rgn]))) , Average Acuity of Untested Poisson Subset[Rgn]) + 1 Units: dmnl

268) PseudoCFR Units: dmnl

*269) R Effective Reproduction Rate[Rgn] = ZIDZ (Infection Rate[Rgn] , Total Weighted Infected Population[Rgn]) * Total Disease Duration Units: dmnl*

270) Reaching Testing Gate[Rgn] = Infected pre Detection[Rgn] / Onset to Detection Delay Units: Person/Day

271) Realistic R0 = sum (if then else (R Effective Reproduction Rate[Rgn!] > MaxRTresh , 1, 0)) Units: dmnl

272) Recent Detected Infections[Rgn] = SMOOTHI (Positive Tests of Infected[Rgn] , Time to Respond with Tests , 0) Units: Person/Day

273) Recovered Unconfirmed[Rgn] = INTEG(Recovery of Untested[Rgn] , 0) Units: Person

*274) Recovery of Confirmed[Rgn] = Tested Untreated Resolution[Rgn] * (1 - Fatality Rate Untreated[Rgn,Tested]) Units: Person/Day*

275) Recovery of Untested[Rgn] = ("Infected Unconfirmed Post-Detection"[Rgn] / "Post-Detection Phase Resolution Time") - Deaths of Symptomatic Untested[Rgn] Units: Person/Day

276) Reference COVID Hospitalization Fraction Confirmed[Rgn] = 0.7 Units: dmnl

277) Reference Force of Infection[Rgn] = 0.6 Units: 1/Day

*278) Reference Hospital Density = 6.06 Units: Person/(Km*Km)*

279) RegionalInputs[UpAdj,Rgn] = Log (Time to Upgrade Risk[Rgn] , 10)

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

280) RegionalInputs[DwnAdj,Rgn] = Log (Time to Downgrade Risk[Rgn] , 10)
281) RegionalInputs[RFI,Rgn] = Reference Force of Infection[Rgn]
282) RegionalInputs[PMT,Rgn] = Sensitivity Post Mortem Testing to Capacity[Rgn]
283) RegionalInputs[RfSkTs,Rgn] = Baseline Daily Fraction Susceptible Seeking Tests[Rgn]
284) RegionalInputs[WRpPIn,Rgn] = Weight on Reported Probability of Infection[Rgn]
285) RegionalInputs[MInfTs,Rgn] = Multiplier Recent Infections to Test[Rgn]
286) RegionalInputs[MnCnFrc,Rgn] = Min Contact Fraction[Rgn]
287) RegionalInputs[SnCnRdUt,Rgn] = Sensitivity of Contact Reduction to Utility[Rgn]
288) RegionalInputs[CfImCn,Rgn] = Confirmation Impact on Contact[Rgn]
289) RegionalInputs[ImPDnHs,Rgn] = Impact of Population Density on Hospital Availability[Rgn]
290) RegionalInputs[ImTrFt,Rgn] = Impact of Treatment on Fatality Rate[Rgn]
291) RegionalInputs[DrdFac,Rgn] = Log (Dread Factor in Risk Perception[Rgn] , 10)
292) RegionalInputs[MxHsFr,Rgn] = Reference COVID Hospitalization Fraction Confirmed[Rgn]
293) RegionalInputs[BsFtRt,Rgn] = Base Fatality Rate for Unit Acuity Net[Rgn]
294) RegionalInputs[SnsWth,Rgn] = Sensitivity to Weather Net[Rgn]
295) RegionalInputs[Acty,Rgn] = Covid Acuity Relative to Flu Net[Rgn]
296) RegionalInputs[SnFtAc,Rgn] = Sensitivity of Fatality Rate to Acuity Net[Rgn]
297) RegionalInputs[TtAsyFr,Rgn] = Total Asymptomatic Fraction Net[Rgn]
298) RegionalInputs[ObsImp,Rgn] = Sens Obesity Impact Net[Rgn]
299) RegionalInputs[ChrImp,Rgn] = Sens Chronic Impact Net[Rgn]
300) RegionalInputs[LivImp,Rgn] = Sens Liver Impact Net[Rgn]
301) RegionalInputs[MTrAsym,Rgn] = Multiplier Transmission Risk for Asymptomatic Net[Rgn]
302) Relative Risk of Transmission by Hospitalized = 1 Units: dmnl
303) Relative Risk of Transmission by Presymptomatic = 1 Units: dmnl
304) Reported Hazard of Infection[Rgn] = Positive Tests of Infected[Rgn] / Susceptible[Rgn] Units: 1/Day
305) Response Policy Time On = 1000 Units: Day
306) Response Policy Weight[pdim] = 0 Units: dmnl
307) Rgn :
Albania,Argentina,Armenia,Australia,Austria,Azerbaijan,Bahrain,Bangladesh,Belarus,Belgium,Bolivia,Bosnia,Bulgaria,Canada,Chile,Colombia,CostaRica,Croatia,Cuba,CzechRepublic,Denmark,Ecuador,ElSalvador,Estonia,Ethiopia,Finland,France,Germany,Ghana,Greece,Hungary,Iceland,India,Indonesia,Iran,Ireland,Israel,Italy,Japan,Kazakhstan,Kenya,Kuwait,Kyrgyzstan,Latvia,Lithuania,Luxembourg,Malaysia,Maldives,Mexico,Morocco,Nepal,Netherlands,NewZealand,Nigeria,NorthMacedonia,Norway,Pakistan,Panama,Paraguay,Peru,Philippines
308) ,Poland,Portugal,Qatar,Romania,Russia,SaudiArabia,Senegal,Serbia,Singapore,Slovakia,Slovenia,SouthAfrica,SouthKorea,Spain,Sweden,Switzerland,Thailand,Tunisia,Turkey,UAE,UK,Ukraine,USA
309) Rgn1 : Rgn
310) SAVEPER = 1 Units: Day
311) Sens Chronic Impact = 1e-06 Units: dmnl
*312) Sens Chronic Impact Net[Rgn] = INITIAL(Sens Chronic Impact * (1 - SW Gen[ChrImp]) + SW Gen[ChrImp] * InputAve[ChrImp]) Units: dmnl*
313) Sens Liver Impact = 1e-06 Units: dmnl
*314) Sens Liver Impact Net[Rgn] = INITIAL(Sens Liver Impact * (1 - SW Gen[LivImp]) + SW Gen[LivImp] * InputAve[LivImp]) Units: dmnl*
315) Sens Obesity Impact = 1e-06 Units: dmnl
*316) Sens Obesity Impact Net[Rgn] = INITIAL(Sens Obesity Impact * (1 - SW Gen[ObsImp]) + SW Gen[ObsImp] * InputAve[ObsImp]) Units: dmnl*
317) SensCovidUntestedAdmission = 1 Units: dmnl
318) Sensitivity of Contact Reduction to Utility[Rgn] = 15 Units: dmnl
*319) Sensitivity of Contact Reduction to Utility Net[Rgn] = if then else (Response Policy Time On < Time , Sensitivity of Contact Reduction to Utility Policy * Response Policy Weight[scuP] + (1 - Response Policy Weight[scuP]) * Sensitivity of Contact Reduction to Utility[Rgn] , Sensitivity of Contact Reduction to Utility[Rgn]) Units: dmnl*
320) Sensitivity of Contact Reduction to Utility Policy = 10 Units: dmnl
321) Sensitivity of COVID Test = 0.7 Units: dmnl
322) Sensitivity of Fatality Rate to Acuity[Rgn] = 2 Units: dmnl
*323) Sensitivity of Fatality Rate to Acuity Net[Rgn] = INITIAL(Sensitivity of Fatality Rate to Acuity[Rgn] * (1 - SW Gen[SnFtAc]) + SW Gen[SnFtAc] * InputAve[SnFtAc]) Units: dmnl*
324) Sensitivity Post Mortem Testing to Capacity[Rgn] = 1 Units: dmnl
325) Sensitivity to Weather = 0.76 Units: dmnl

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

326) *Sensitivity to Weather Net[Rgn] = INITIAL(Sensitivity to Weather * (1 - SW Gen[SnsWth]) + SW Gen[SnsWth] * InputAve[SnsWth]) Units: dmnl*
327) *Series : Infection,Death,Test*
328) *SeriesErrorTerm[Rgn,Series] = if then else (DataCmltOverTime[Rgn,Series] = :NA:, 0, (abs (DataCmltOverTime[Rgn,Series] - SimCmltOverTime[Rgn,Series])) ^ CmltErrPW) / (BaseError + DataCmltOverTime[Rgn,Series]) * CmltPenaltyScl * CmltToInclude[Series] * DataIncluded[Rgn] Units: dmnl*
329) *Sim Pseudo Case Fatality[Rgn] = ZIDZ (Cumulative Deaths of Confirmed[Rgn] , Cumulative Confirmed Cases[Rgn]) Units: dmnl*
330) *SimCmltOverTime[Rgn,Infection] = Cumulative Confirmed Cases[Rgn]*
331) *SimCmltOverTime[Rgn,Death] = Cumulative Deaths of Confirmed[Rgn]*
332) *SimCmltOverTime[Rgn,Test] = Cumulative Tests Conducted[Rgn] Units: Person*
333) *SimFlowOverTime[Rgn,Infection] = Post Mortem Test Rate[Rgn] + Positive Tests of Infected[Rgn]*
334) *SimFlowOverTime[Rgn,Death] = Post Mortem Test Rate[Rgn] + Deaths of Confirmed[Rgn] + Hospitalized Infectious Deaths[Rgn,Tested]*
335) *SimFlowOverTime[Rgn,Test] = Total Simulated Tests[Rgn] Units: Person/Day*
336) *SimTestRate[Rgn] = Total Simulated Tests[Rgn] Units: Person/Day*
337) *SqrdErr[Rgn,Series] = if then else (FlowResiduals[Rgn,Series] = :NA:, :NA:, FlowResiduals[Rgn,Series] ^ 2) Units: Person*Person/(Day*Day)*
338) *Susceptible[Rgn] = INTEG(- Infection Rate[Rgn] , Initial Population[Rgn]) Units: Person*
339) *SuscFrac[Rgn] = Susceptible[Rgn] / Population[Rgn] Units: dmnl*
340) *SW EndoAve = INITIAL(if then else (ELMCOUNT(Rgn) > 1, 1, 0)) Units: dmnl*
341) *SW Gen[PriorGen] = 0 Units: dmnl*
342) *Switch for Government Response[Rgn] = if then else (Time > Government Response Start Time[Rgn] , 1, 0) Units: dmnl*
343) *Symptomatic Fraction in Poisson[Rgn] = INITIAL(1 - exp (- Covid Acuity[Rgn])) Units: dmnl*
344) *Symptomatic Fraction Negative[Rgn] = INITIAL(1 - exp (- Flu Acuity)) Units: dmnl*
345) *Symptomatic Infected to Testing[Rgn] = Positive Testing of Infected Untreated[Rgn] + Hospital Admission Infectious[Rgn,Tested] Units: Person/Day*
346) *t3[Rgn] = (-9 * b[Rgn] + 1.7321 * Sqrt (4 * a[Rgn] ^ 3 + 27 * b[Rgn] ^ 2)) ^ (1 / 3) Units: dmnl*
347) *talp = 5 Units: dmnl*
348) *Tested Untreated Resolution[Rgn] = Infectious Confirmed Not Hospitalized[Rgn] / "Post-Detection Phase Resolution Time" Units: Person/Day*
349) *TestErrorFrac = 0.0001 Units: dmnl*
350) *TestFlowErr[Rgn] = ((DataFlowOverTime[Rgn,Test] - SimFlowOverTime[Rgn,Test]) * WTestFlowErr[Rgn]) ^ 2 Units: dmnl*
351) *Testing Capacity Net of Post Mortem Tests[Rgn] = Active Test Rate[Rgn] - Post Mortem Tests Total[Rgn] Units: Person/Day*
352) *Testing Demand[Rgn] = Positive Candidates Interested in Testing Poisson Subset[Rgn] * Symptomatic Fraction in Poisson[Rgn] + Potential Test Demand from Susceptible Population[Rgn] * Symptomatic Fraction Negative[Rgn] Units: Person/Day*
353) *Testing on Living[Rgn] = min (Testing Capacity Net of Post Mortem Tests[Rgn] , Testing Demand[Rgn]) Units: Person/Day*
354) *Tests on Negative Patients[Rgn] = Testing on Living[Rgn] * ZIDZ (Indicated fraction negative demand tested[Rgn] * Potential Test Demand from Susceptible Population[Rgn] , Indicated fraction negative demand tested[Rgn] * Potential Test Demand from Susceptible Population[Rgn] + Indicated fraction positive demand tested[Rgn] * Positive Candidates Interested in Testing Poisson Subset[Rgn]) Units: Person/Day*
355) *Tests Per Million[Rgn] = Cumulative Tests Data[Rgn] / Initial Population[Rgn] * 1e+06 Units: dmnl*
356) *ThrsInc[Rgn] = Max (FracThresh * MaxData[Rgn] , 50) Units: Person*
357) *TIME STEP = 0.25 Units: Day*
358) *Time to Adjust Testing = 30 Units: Day*
359) *Time to Downgrade Risk[Rgn] = 60 Units: Day*
360) *Time to Downgrade Risk Net[Rgn] = if then else (Response Policy Time On < Time , Time to Downgrade Risk Policy * Response Policy Weight[dgtP] + (1 - Response Policy Weight[dgtP]) * Time to Downgrade Risk[Rgn] , Time to Downgrade Risk[Rgn]) Units: Day*
361) *Time to Downgrade Risk Policy = 300 Units: Day*
362) *Time to Herd Immunity[Rgn] = XIDZ (Herd Immunity Fraction * Susceptible[Rgn] , Total Weighted Infected Population[Rgn] / Total Disease Duration , 0) Units: Day*
363) *Time to Respond with Tests = 5 Units: Day*
364) *Time to Upgrade Risk[Rgn] = 10 Units: Day*

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

365) Total Asymptomatic Fraction[Rgn] = 0.5 Units: dmnl
*366) Total Asymptomatic Fraction Net[Rgn] = INITIAL(Total Asymptomatic Fraction[Rgn] * (1 - SW Gen[TtAsyFr]) + SW Gen[TtAsyFr] * InputAve[TtAsyFr]) Units: dmnl*
367) Total Covid Hospitalized[Rgn] = sum (Hospitalized Infectious[Rgn,TstSts!]) Units: Person
368) Total Disease Duration = Onset to Detection Delay + "Post-Detection Phase Resolution Time" + Incubation Period Units: Day
369) Total Simulated Tests[Rgn] = Post Mortem Tests Total[Rgn] + Testing on Living[Rgn] Units: Person/Day
370) Total Test on Covid Patients[Rgn] = Max (0, min (Positive Candidates Interested in Testing Poisson Subset[Rgn] , Testing on Living[Rgn] - Tests on Negative Patients[Rgn])) Units: Person/Day
371) Total to Official Cases Simulated[Rgn] = ZIDZ (Cumulative Cases[Rgn] , SimCmltOverTime[Rgn,Infection]) Units: dmnl
372) Total Weighted Infected Population[Rgn] = Infected pre Detection[Rgn] + "Pre-Symptomatic Infected"[Rgn] + Weighted Infected Post Detection Gate[Rgn] Units: Person
*373) Transmission Multiplier for Confirmed[Rgn] = INITIAL(Baseline Transmission Multiplier for Untested Symptomatic * Confirmation Impact on Contact[Rgn]) Units: dmnl*
*374) Transmission Multiplier for Hospitalized[Rgn,TstSts] = INITIAL(Baseline Transmission Multiplier for Untested Symptomatic * Relative Risk of Transmission by Hospitalized * if then else (TstSts = 1, Confirmation Impact on Contact[Rgn] , 1)) Units: dmnl*
*375) Transmission Multiplier Pre Detection[Rgn] = INITIAL(Baseline Transmission Multiplier for Untested Symptomatic * (1 - Total Asymptomatic Fraction Net[Rgn]) + Total Asymptomatic Fraction Net[Rgn] * Baseline Risk of Transmission by Asymptomatic[Rgn]) Units: dmnl*
*376) Transmission Multiplier Presymptomatic[Rgn] = INITIAL((Baseline Transmission Multiplier for Untested Symptomatic * Relative Risk of Transmission by Presymptomatic) * (1 - Total Asymptomatic Fraction Net[Rgn]) + Total Asymptomatic Fraction Net[Rgn] * Baseline Risk of Transmission by Asymptomatic[Rgn] * Relative Risk of Transmission by Presymptomatic) Units: dmnl*
377) TstInc[Rgn] = Active Test Rate[Rgn] Units: Person/Day
378) TstSts : Tested,Notest
379) Untested PMAS Gap with Tested[Rgn] = (1 - Allocated Fration NonCOVID Hospitalized[Rgn]) ^ SensCovidUntestedAdmission Units: dmnl
380) Untested symptomatic Infected to Hospital[Rgn] = Hospital Admission Infectious[Rgn,Notest] Units: Person/Day
*381) Utility from Limited Activities[Rgn] = exp (Sensitivity of Contact Reduction to Utility Net[Rgn] * Fractional Value of Limited Activities) Units: dmnl*
*382) Utility from Normal Activities[Rgn] = exp (Sensitivity of Contact Reduction to Utility Net[Rgn] * (1 - Perceived Risk of Life Loss[Rgn])) Units: dmnl*
*383) Voluntary Reduction in Contacts[Rgn] = F[Rgn] / F0[Rgn] * (1 - Min Contact Fraction[Rgn]) + Min Contact Fraction[Rgn] Units: dmnl*
*384) W Ave Acuity Hospitalized[Rgn] = ZIDZ (sum (Average Acuity Hospitalized[Rgn,TstSts!] * Hospitalized Infectious[Rgn,TstSts!]) , sum (Hospitalized Infectious[Rgn,TstSts!])) Units: dmnl*
385) Weather Effect on Transmission[Rgn] = CRW[Rgn] ^ Sensitivity to Weather Net[Rgn] Units: dmnl
386) Weight Max in Test Goal = 0 Units: dmnl
387) Weight on Reported Probability of Infection[Rgn] = 0.78 Units: dmnl
*388) Weighted Infected Post Detection Gate[Rgn] = "Infected Unconfirmed Post-Detection"[Rgn] + Infectious Confirmed Not Hospitalized[Rgn] + sum (Hospitalized Infectious[Rgn,TstSts!]) * "Post-Detection Phase Resolution Time" / Hospitalized Resolution Time Units: Person*
*389) WTestFlowErr[Rgn] = if then else (DataFlowOverTime[Rgn,Test] = :NA:, 0, 1 / Max (10, DataFlowOverTime[Rgn,Test] * TestErrorFrac)) Units: Day/Person*
390) Y[Rgn] = min (1, Max (1e-06, 1 - exp (- Extrapolated Estimator[Rgn]))) Units: dmnl
391) Ymix[Rgn,p2] = - b[Rgn] / (1 + a[Rgn])
*392) Ymix[Rgn,p3] = (Sqrt (a[Rgn] ^ 2 - 4 * b[Rgn]) - a[Rgn]) / 2*
*393) Ymix[Rgn,p4] = (-0.87358 * a[Rgn]) / t3[Rgn] + 0.38157 * t3[Rgn] Units: dmnl*

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

S6- References

1. D. F. Gudbjartsson *et al.*, Spread of SARS-CoV-2 in the Icelandic population. *New England Journal of Medicine*, (2020).
2. W. Yang *et al.*, Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19): A multi-center study in Wenzhou city, Zhejiang, China. *Journal of Infection*, (2020).
3. M. Roser, H. Ritchie, E. Ortiz-Ospina, J. Hasell, in *Our World in Data*. (2020).
4. W. Wang *et al.*, Detection of SARS-CoV-2 in different types of clinical specimens. *Jama* **323**, 1843-1844 (2020).
5. Y. Fang *et al.*, Sensitivity of chest CT for COVID-19: comparison to RT-PCR. *Radiology*, 200432 (2020).
6. Y. Li *et al.*, Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19. *J Med Virol* **92**, 903-908 (2020).
7. R. Xu *et al.*, Weather Conditions and COVID-19 Transmission: Estimates and Projections. *medRxiv*, (2020).
8. W. J. Guan *et al.*, Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* **382**, 1708-1720 (2020).
9. Z. Wu, J. M. McGoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. *Jama* **323**, 1239-1242 (2020).
10. A. V. Dorn, R. E. Cooney, M. L. Sabin, COVID-19 exacerbating inequalities in the US. *Lancet* **395**, 1243-1244 (2020).
11. T. W. Russell *et al.*, Estimating the infection and case fatality ratio for coronavirus disease (COVID-19) using age-adjusted data from the outbreak on the Diamond Princess cruise ship, February 2020. *Euro Surveill* **25**, (2020).
12. A. Basu, Estimating The Infection Fatality Rate Among Symptomatic COVID-19 Cases In The United States. *Health Aff (Millwood)*, 101377hlthaff202000455 (2020).
13. E. Lavezzo *et al.*, Suppression of COVID-19 outbreak in the municipality of Vo, Italy. *medRxiv*, (2020).
14. K. Mizumoto, K. Kagaya, A. Zarebski, G. Chowell, Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. *Euro Surveill* **25**, (2020).
15. D. Sutton, K. Fuchs, M. D'Alton, D. Goffman, Universal Screening for SARS-CoV-2 in Women Admitted for Delivery. *N Engl J Med* **382**, 2163-2164 (2020).
16. N. M. Linton *et al.*, Incubation Period and Other Epidemiological Characteristics of 2019 Novel Coronavirus Infections with Right Truncation: A Statistical Analysis of Publicly Available Case Data. *J Clin Med* **9**, (2020).
17. H. Rahmandad, K. Hu, Modeling the rework cycle: capturing multiple defects per task. *Syst Dynam Rev* **26**, 291-315 (2010).
18. A. Gelman, J. Hill, *Data analysis using regression and multilevel/hierarchical models*. (Cambridge university press, 2006).
19. J. A. Vrugt *et al.*, Accelerating Markov chain Monte Carlo simulation by differential evolution with self-adaptive randomized subspace sampling. *International Journal of Nonlinear Sciences and Numerical Simulation* **10**, 273-290 (2009).
20. E. Dong, H. Du, L. Gardner, An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect Dis* **20**, 533-534 (2020).
21. Z. Lipton, J. Ellignton, K. Riely. (The Atlantic).
22. Wikipedia. (2020).

medRxiv preprint doi: https://doi.org/10.1101/2020.06.24.20139451; this version posted June 26, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license .

23. WHO. (2020).
24. W. Bank. (2020).
25. J. Wu, A. McCann, J. Katz, E. Peltier. (2020).
26. B. Dale, N. Stylianou. (BBC, 2020).
27. N. Ghaffarzadegan, H. Rahmandad, Simulation-based Estimation of the Early Spread of COVID-19 in Iran: Actual versus Confirmed Cases. *Syst Dynam Rev* **Forthcoming**, (2020).
28. R. Verity *et al.*, Estimates of the severity of coronavirus disease 2019: a model-based analysis. *The Lancet infectious diseases*, (2020).
29. Z. Du *et al.*, Serial interval of COVID-19 among publicly reported confirmed cases. *Emerging infectious diseases* **26**, 1341 (2020).
30. H. Nishiura, N. M. Linton, A. R. Akhmetzhanov, Serial interval of novel coronavirus (COVID-19) infections. *International journal of infectious diseases*, (2020).
31. E. Dong, H. Du, L. Gardner, An interactive web-based dashboard to track COVID-19 in real time. *The Lancet Infectious Diseases*.